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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Ras proteins are monomeric GTP binding proteins that are situated at the 
inner leaflet of the plasma membrane. At the plasma membrane, Ras proteins 
act as binary molecular switches to relay information from activated receptors to 
effectors that ultimately mediate a variety of cellular responses (11). Since 1982, 
when it was discovered that activated Ras proteins were able to transform rodent 
fibroblast cells, they have been the subject of intense investigation. Genetic 
studies have subsequently identified mutations in one or another of the three 
Ras genes in -30% of all human tumors (49). 
In order for normal or oncogenic Ras proteins to participate in cellular 
events, they must be in the active GTP-bound state and located at the inner 
surface of the plasma membrane. A change in the conformation upon binding 
of GTP allows Ras proteins to associate with and activate a large number of 
diverse downstream effectors. Possible Ras effectors include Ras GTPase 
activating proteins (RasGAPs), Raf kinases, members of the phosphoinositide 3-
kinase (PI3K) family, and RalGDS (Fig. 1) (49, 52, 87). Studies employing either 
dominant-inhibitory or constitutively active mutants of these effectors suggest 
that their activation is essential for complete cell transformation or 
Figl. Putative Ras effectors 
PI3-K RalGDS Raf pl20GAP 
differentiation (11, 87). Although the 
number of Ras effector proteins continues 
to increase, the individual contributions of 
these proteins to Ras mediated cellular 
transformation is not fully understood. 
However, it is suspected that no one 
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specific effector will be the sole mediator of Ras growth-promoting actions. 
The identification of multiple Ras binding proteins has supported the idea 
that multiple signal transduction pathways cause a diverse array of cellular 
effects mediated by Ras. Mutagenesis and structural analysis studies suggest that 
the core Ras effector-binding sequence (residues 32-40) and some flanking 
residues are clearly important for Ras protein interactions with its effectors (95). 
Despite the large number of effectors identified, mutational analysis has failed to 
identify additional, distinct regions in Ras that are likely to mediate interaction 
with effectors. Therefore, it is unclear how effector interaction with Ras is 
controlled since each of the possible effectors must compete for the same binding 
site on Ras. 
In addition to regulation by the GTP/GDP cycle, plasma membrane 
localization of Ras is critical for biological activity. Mutagenic experiments 
indicate that this positioning is accomplished by a series of post-translational 
modifications that begin with farnesylation of a cysteine residue four amino 
acids from the carboxy-terminus. As the first and prerequisite step for further 
processing, farnesylation of Ras appears to be critical for both membrane binding 
and biological functions in vivo (8, 17, 23, 27, 80, 99). Mutations in normal and 
oncogenic Ras proteins that prevent farnesylation are found to block post-
translational processing, abolish membrane binding, and suppress Ras mediated 
cellular transformation and differentiation (10, 20, 27, 28, 94). Likewise, yeast 
cells in which farnesylation of the Rasl and Ras2 proteins is prevented are not 
viable (2, 56, 77). These results suggest that the famesyl moiety is required for 
membrane targeting and biological activity of cellular or oncogenic Ras proteins. 
Once the famesyl moiety is attached, certain Ras proteins also become 
palmitoylated. This second post-translational modification appears to also 
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contribute to Ras membrane association and biological activity since mutant 
HRas proteins which are prenylated but cannot be palmitoylated 
(Cysl81Ser/Cysl84Ser) are poorly membrane bound (<20%), become mis-directed 
to internal membranes, and have very low transforming activity (94). These 
observations demonstrate that palmitoylation is also a critical modification, 
along with famesylation, and have prompted many laboratories to speculate that 
palmitate (rather than the famesyl modification) is primarily responsible for Ras 
membrane binding and therefore plays a significant role in Ras function. 
Importantly, the individual role(s) of famesyl and palmitate are unclear. 
Several models have been proposed for how lipids may control Ras 
function. The widely accepted paradigm is that the role of lipids is non-specific 
and they simply provide a hydrophobic region to aid in Ras-membrane 
interactions. This allows the remainder of the protein to interact with signaling 
partners (17, 20, 56, 81). However, recent studies with HRas suggest that the 
lipids, mainly famesyl, may contribute to a unique structural domain at the C-
terminus that promotes Ras-Raf interactions. In separate studies, it has been 
reported that the C-terminal modifications of HRas are necessary for complete 
activation of c-Rafl or B-Raf through the kinase's cysteine-rich domain (30, 50, 
61, 75). Further, evidence for differential activities of the four Ras isoforms has 
begun to accumulate. These studies indicate that K4B-Ras is a more potent 
stimulator of c-Rafl activity, while HRas promotes increased PI3-kinase activity 
(75, 86, 97). Interestingly, these proteins are identical except for their last 30 
amino acids. A third model suggests that the varying modes of membrane 
attachment, two distinct lipids versus a lipid and a polybasic domain (Fig. 2), 
influence Ras activity by altering localization of the Ras isoforms within the 
plasma membrane (i.e. lipid rafts, caveolae, etc). Taken together, these studies 
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Palmitoylation 
HRas QHKLRKLNPPDESGPGCMSCKlCVLS 
NRas QYRMKKLNSSDDGTQGCM3LPCVVM 
KRas4A QYRLKKI SKEEKTPGCVKI KKCI IM 
KRas4B  RKHKE KMS KDGKKKKKI^ S KT K|CVIM 
polybasic CAAX 
Motif 
Fig 2. Last 25 amino adds of 4 Ras isoforms 
imply that the lipid modified C-terminus of Ras may be involved in and 
required for specific associations of Ras with its target proteins. 
HRas ISOgcMSCKCVLS 
EXTRas ISOGCMSCKCVLKKKKKK 
G43Ras iMVCCMRRTLQVnTEYKLVV 
GAP43 HRas 
Fig. 3 Amino acid sequence of the C-terminus 
of HRas and ExtRas proteins and N-terminus of 
G43Ras proteins. 
In our studies of HRas lipidation, we constructed two novel, activated 
(Q61L) HRas proteins which lacked the appropriate signal sequence for 
famesylation (CVLS or CAAX motif). These Ras proteins were referred to as 
G43:HRas61L and Ext61L. The G43HRas61L mutant was created by fusing the first 
ten amino acids of the GAP43 protein, an amino-terminal palmitoylated protein, 
to the amino terminus of HRas61L which contained a mutation at position 186 
to prevent famesylation (Cysl86Ser). This combination resulted in a chimeric 
HRas protein with an unaltered C-terminus, except for the lack of a famesyl (Fig. 
3). The Ext61L mutant was constructed by replacing the serine of the CaaX motif. 
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the signal sequence for prenylation, with six lysines. This addition resulted in an 
HRas protein that had lost its ability to be famesylated but retained the natural 
sites for palmitoylation. These mutants were used to determine (1) if 
farnesylation is a requirement for palmitoylation, (2) the contribution of 
palmitates to HRas membrane binding and biological activity, and (3) the 
contributions of the HRas C-terminus to specific effector interactions. 
Dissertation Organization 
This dissertation begins with a general introduction and is followed by 
three papers as three chapters and a general conclusion. The general 
introduction provides the background and significance of the work presented in 
this dissertation and includes an introduction, the dissertation organization, and 
background to this study. The background includes sections covering properties 
of Ras, regulation of Ras biological activity, mechanisms for HRas lipid 
modifications, and Ras signal transduction. 
The three papers. Chapters 2-4, are written in journal article format for 
publication and follow the style and subsection format as per the requirements of 
the journals. Chapter 2 entitled "A non-farnesylated HRas protein can be 
palmitoylated and trigger potent differentiation and transformation" has been 
published in the Journal of Biological Chemistry. Chapter 3 entitled "HRas C-
terminal mutation changes PI3-K and Raf activation" is a manuscript submitted 
for publication to the Journal of Biological Chemistry. Chapter 4 entitled 
"Transient palmitoylation supports HRas membrane binding but only partial 
biological activity" has been published in Biochemistry. The experiments 
performed in each chapter are of a collaborative nature and required a 
multidisciplinary approach. Accordingly, the papers are credited to multiple 
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authors. I am the major contributor to Chapters 2 and 3 and, therefore, the first 
author. The bulk of the studies reported in Chapter 4 were carried out by Sarah 
Coats, who is the first author. However, my contributions were key to the 
conclusions reached, without which this paper could not have been published. 
Since I am not the primary author of Chapter 4, I have included a statement 
about my specific contributions to this paper at the beginning of the chapter. 
Chapter 5 is a general discussion of the results presented in the three papers and 
the conclusions drawn from them. 
Background 
Properties of Ras 
There are four mammalian Ras proteins: K4A- and K4B-, which are 
generated from alternatively spliced RNAs, plus HRas and NRas. These 4 
proteins are 85% identical at the amino acid level and they belong to the large 
Ras superfamily of small GTP binding proteins. This family also contains two 
subfamilies: (1) the Rho family of GTP binding proteins, which control actin 
cytoskeletal reorganization and (2) the Rab family, which regulate vesicular 
trafficking as reviewed by Macara et al (52). 
Members of the Ras superfamily are monomeric proteins defined by three 
highly conserved loop sequences. The first motif, GxxxxGK(S/T), is found in 
many purine binding proteins (89) and is thought to wrap around the P 
phosphate group of guanine nucleotides (5, 79, 93). This domain is commonly 
referred to as the phosphate-binding loop or the glycine-rich loop. The second 
motif, DxxG, is positioned relatively close to the phosphate-binding loop and is 
thought to be critical in the conformational change between the GDP and GTP 
forms of Ras (5, 7, 55, 79). Finally, the third motif, NKxD, interacts specifically 
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with the guanine (5, 46, 79). In addition to the above three conserved sequences, 
which comprise the GTP-binding motif, Ras family members contain a core 
effector loop. This loop is identical among the four Ras proteins and contains 
the eight amino acid Switch I domain (residues 32-40). Recent evidence utilizing 
effector domain mutants suggests that, in a GTP bound state, it is the Switch I 
domain that interacts directly with downstream signaling partners (35, 38, 72, 74, 
91). Interestingly, upon binding GTP, the Switch I domain undergoes a 
substantial conformational change by having residues 31-38 flip almost 180° (69, 
96). This conformational change signals the GTP-binding state of Ras to other 
proteins in the cell. A second switch domain. Switch II (residues 61-77), is also 
affected by the GTP binding state of Ras (51, 55, 57, 64, 65). However, the effects of 
the Y phosphate on this region have been difficult to distinguish but do not seem 
to be as dramatic as those occuring in Switch I (51, 55, 57, 96). 
Ras proteins were first identified, in mutated form, as transforming agents 
of the Harvey and Kirsten murine sarcoma viruses and have since been 
implicated in 30% of all human carcinomas (49). Although these oncogenic Ras 
proteins promote many of the aberrant activities of cancer cells, normal Ras 
proteins are required to regulate activities such as cell growth, differentiation, or 
apoptosis. 
While the individual contribution(s) of the four Ras proteins to various 
cellular processes are not understood, the question of Ras specificity in signal 
transduction cascades that govern both normal and malignant cell growth is 
critical. Past studies have concluded that the four homologs of Ras are 
functionally redundant. Among the observations used to draw this conclusion 
were (1) manunalian Ras proteins are 96% identical at the amino acid level from 
residues 1-155, (2) the first 86 residues, which harbor the effector domain, are 
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100% identical, and (3) with the exception of K4A-Ras, all Ras proteins appear to 
be ubiquitously expressed (22, 47, 66) and interact with the same downstream 
signaling partners in vitro (as reviewed by (11, 54, 87). Further support has been 
provided by studies in yeast which suggest that loss of function of both genes, 
Rasl and Ras2, was required to produce a lethal phenotype (36). 
While recent reports imply that each mammalian Ras protein may have 
different biological roles, studies utilizing gene knockout mice implicate K-Ras, 
but not H- or N-Ras, as important in mouse embryogenesis (33, 83). Analysis of 
human cancers has determined that specific tumors often contain mutated 
versions of specific Ras isoforms. For instance, mutant HRas proteins are rarely 
detected in human cancers, while mutant forms of K-Ras are found in >90% of 
pancreatic, 50% of colon, and 30% of lung carcinomas and mutant N-Ras 
proteins are commonly associated with acute leukemias (4). In addition to this 
physiological evidence, recent biochemical analysis suggests that the four 
isoforms of Ras differentially interact with and activate specific downstream 
effectors in vivo (86, 97). Importantly, the only region of significant difference 
between these four Ras proteins is in their lipidated, C-terminal hj^ervariable 
domain (HVD) (residues 164-189). Taken together, these biochemical and genetic 
results imply that the C-terminus may be an important contributor to the 
oncogenic activity of mutated Ras proteins. 
Regulation of Ras Biological Activity 
GDP/GTP cycle 
The most completely characterized mechanism for controlling Ras 
biological activity is the regulation of binding and hydrolysis of GTP, commonly 
referred to as the GDP/GTP cycle. Ras proteins themselves possess a low level of 
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intrinsic GTP hydrolytic activity. Therefore, cellular control of this cycle is 
driven by two types of regulatory proteins. Guanine nucleotide exchange factors 
(GEFs), which include Sos 1, Sos 2, Ras-GRF/CDC25M'^, Ras-GRF2, and Ras-
GRP, function by inducing the release of GDP from Ras (3, 32, 34, 49). This 
release of GDP results in the rapid binding of GTP, due to the high concentration 
of free GTP relative to free GDP in the cell (3, 32). Furthermore, Ras has a greater 
affinity for GTP than for GDP (32). Conversely, Ras is negatively regulated by 
GTPase-activating proteins (GAPs) that stimulate hydrolysis of Ras-GTP and 
return Ras to the inactive GDP-bound state (3, 62). Interestingly, Ras proteins 
with single amino acid substitutions at positions 12, 13, or 61 are insensitive to 
GAP activity and become locked in the active, GTP-bound state, leading to 
deregulation of Ras function (87). 
Membrane binding 
The second mechanism regulating Ras activity is related to the correct 
localization of Ras proteins to the inner leaflet of the plasma membrane. This 
localization arises from modifications that occur at the carboxy terminus of each 
Ras protein (15, 99). The first modification consists of the attachment of famesyl, 
via a thioether linkage, to a cysteine residue precisely four amino acids from the 
C-terminus (Cysl86). This cysteine is part of the CaaX motif that functions as a 
recognition signal for a specific prenyl transferase which in the case of Ras 
proteins is famesyl transferase. Subsequent to farnesylation, the three C-
terminal "aaX" residues are proteolytically removed and the farnesylated 
cysteine becomes methylated in an enzyme catalyzed process (13, 99). These 
enzyme-mediated modifications are prenyl-dependent and occur at the 
endoplasmic reticulum (14, 25, 68). This pathway has now been foimd to act on 
many prenyl proteins, including a large contingent in the Ras Superfamily. 
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Although the addition of famesyl causes the C-tenninus of Ras to be more 
hydrophobic, this does not result in stable plasma membrane association of Ras, 
nor does it lead to specific plasma membrane targeting (20, 27, 43, 78, 94). The 
current paradigm suggests that a second signal acts in cooperation with the 
famesyl to promote correct targeting of Ras to the plasma membrane. This signal 
has been previously demonstrated to be palmitoylation of additional C-terminal 
cysteines (CyslSl and Cysl84 of HRas, CyslSl for N-Ras, and CyslSO for K4A-Ras) 
or, in the case of K4B-Ras, a stretch of basic amino acids (27, 31). Both 
modifications occur within the 30 amino acid hyper-variable domain (residues 
165-186) which separates the highly conserved region of Ras, which contains the 
nucleotide binding domains, from the membrane binding CaaX motif. The 
hypothesis suggests that stable plasma membrane localization of K4A-, N- and 
HRas may result from attachment of palmitate(s) when the Ras proteins contact 
the membrane. Additionally, it is thought that farnesylation facilitates 
palmitoylation by providing an initial membrane-binding signal that allows 
access to the putative palmitoylation machinery. As for K4B-Ras, which does not 
become palmitoylated, the polybasic stretch of amino acids internal to the 
famesyl is thought to promote plasma membrane binding via electrostatic 
interactions with the anionic phospholipids in the plasma membrane. In either 
case, the combination of these post-translational modifications promotes specific 
and sustained plasma membrane binding. 
Studies have demonstrated that both components are essential for plasma 
membrane association and this association is crucial for Ras biological function 
(10, 20, 26, 28, 94). Additionally, the combination of these two signals has been 
used to effectively position a diverse set of otherwise cytosolic proteins to the 
irmer leaflet of the plasma membrane. Yet, it is unclear why two lipids or a lipid 
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and a polybasic stretch of amino acids are required for membrane association, 
and whether these individual lipids have distinct properties that contribute to 
correct positioning or protein-protein interactions. 
Mechanism of HRas lipid modification 
Covalent attachment of lipids is a common modification of many 
mammalian proteins. These modifications help to target normally cytosolic 
signal-transducing proteins, such as Ras, to the cytoplasmic surface of the plasma 
membrane where they relay extracellular signals to intracellular effectors. HRas 
gains the ability to interact with membranes by being modified by 2 types of 
lipids, a farnesyl and two palmitates. Although both lipids are attached to 
cysteine residues at the C-terminal end of the protein, they differ in several other 
respects. 
Addition of a famesyl group is an enzyme catalyzed reaction that occurs in 
the cytoplasm and permanently modifies Ras proteins. Subsequent to 
farnesylation, CyslSl and Cysl84 are modified by palmitic acid via a labile 
thioester linkage (9, 27). In contrast to farnesylation, which has a conserved 
sequence motif, palmitoylation occurs in a wide variety of sequence contexts. For 
example, palmitate addition can occur in the context of other lipid modifications, 
such as prenylation or N-myristoylation, and can be located at the N- or C-
terminus of various proteins. Further, the transient nature of the thioester 
linkage, unlike the thioether bond used to fasten the famesyl moiety to proteins, 
allows continuous cycles of palmitoylation and depalmitoylation, with a 
turnover half-time of 1-2 hours. Presently, the function of this cycling and the 
mechanisms governing its regulation are not clear. The addition and removal of 
palmitate is thought to be regulated by specific enzymes. However, isolation of 
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these enzymes has proven to be extremely difficult. Recently, an eru:yme, APTl, 
that removes palmitates from heterotrimeric G proteins, in vitro and in vivo, 
has been cloned (21). Subsequent in vivo studies have suggested that APTl may 
be a physiological regulator of eNOS palmitoylation (98). However, caveolin, a 
22-kDa palmitoylated integral membrane protein, does not appear to be a 
substrate for APTl (98). Thus, it remains to be determined if this enzyme also 
has specificity for monomeric G proteins such as Ras. 
Ras signal transduction 
Ras proteins, in their GTP bound state, control cell growth, death, and 
differentiation, through alterations in signal transduction cascades that influence 
cell cycle machinery, changes in gene expression, and organization of the actin 
cytoskeleton (11, 76, 87). In recent years the signaling activities influenced by Ras 
proteins has grown much more complex than originally envisioned. It is clear 
that Ras must regulate multiple downstream effectors in order to achieve its 
biologically diverse functions. 
The most-studied of the Ras effector pathways is the Raf kinase cascade. 
Substantial evidence suggests that GTP-bound Ras binds Raf through its core 
effector domain (residues 32-40) and simultaneously recruits Raf to the plasma 
membrane, where additional events lead to the activation of its kinase function 
(58, 85, 88). Upon activation, Raf then phosphorylates and activates the protein 
kinase Mek, which in turn phosphorylates and activates the extracellular 
regulated kinases (ERKs) (18). However, Raf is not the sole mediator of Ras 
function. There is substantial evidence to support the hypothesis that Raf-
independent pathways are critical for mediating Ras function (as reviewed by (11, 
37). Nevertheless, the importance of Raf/MEK/Erk cascade to Bias differentiation 
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and transformation is supported by observations that kinase-deficient mutants of 
Raf-1 and Mek can block Ras-mediated differentiation and transformation (6, 16, 
44). Also, constitutively activated mutants of Raf-1 and Mekl and 2 can cause 
cell differentiation as well as malignant transformation (16, 44, 53). 
Furthermore, kinase-deficient mutants of MAPKs have also been shown to be 
inhibitors of Ras-mediated signaling events (16, 48, 63, 84, 90). Thus, Raf and 
Mek activities are essential for Ras differentiation and transformation. 
In the last five years, a variety of experimental approaches have identified 
several other putative Ras effector proteins, besides Raf, that activate alternative 
signaling pathways required for full Ras function (as reviewed by (11, 37, 87). 
Recently characterized Raf-independent effectors include, phosphoinositide 3-
OH kinase (PI3-kinase) and RalGDS (3, 67, 72, 73). 
PI3-kinase, a lipid kinase that phosphorylates the 3' position of inositol-
containing phospholipids, was identified as a possible Ras effector using yeast 
two hybrid screening for Ras-binding proteins and in vitro binding assays (41, 72, 
74). Subsequently, studies in intact cells suggest that GTP-bound Ras can 
stimulate PI3-kinase activity, and this activity appears to be required for growth 
factor-mediated responses (29, 40-42, 72). Additionally, expression of activated 
Ras is correlated with a significant increase in inositol phosphates containing a 3' 
phosphate group (12, 19, 82). Ras effector domain mutants, that bind and activate 
only a subset of Ras effectors, also implicate PI3-kinase in oncogenic Ras activities 
(35, 73, 91, 92).. Together, these results suggest PI3-kinase is a downstream 
effector of Ras. 
PI3-kinase activity has been speculated to influence Ras signaling through 
production of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 (19, 71, 82). These short-lived 
second messengers are thought to have many functions including stimulation of 
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signaling pathways that lead to activation of Akt kinase, S6 kinase, and protein 
kinase C (12, 82). Recent evidence demonstrates that these signaling molecules 
can also activate GEFs for the Rho family of GTP binding proteins (35), which 
promote actin cytoskeleton rearrangements and may couple Ras and Rac 
pathways (41,45,59,60, 70, 72). 
In contrast to the knowledge of Ras interactions with Raf kinase and PI3-
kinase, the contributions of Ral-GEF activity to Ras transformation or 
differentiation are beginning to emerge. Similar to PI3-kinase, Ral-GEF was 
isolated from a yeast two hybrid library screen for Ras binding proteins. It was 
originally identified as a Ras GEF but was found to function as a GEF for RalA 
and RalB, both of which are members of the Ras Superfamily (1). Evidence for 
Ral-GEF as a Ras effector is largely based on in vitro binding studies (39) and in 
vivo binding needs to be assessed to validate a true interaction. Recent studies in 
PC12 cells showed that inhibitory mutants of RalGEF enhanced NGF-induced 
neurite outgrowths and exit from cell cycle, while the reciprocal mutants 
inhibited NGF-mediated neurite outgrowths and cell cycle arrest (24). However, 
more studies are required to determine if Ral-GEF is a physiologically relevant 
Ras effector. 
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CHAPTER 2. A NON-FARNESYLATED HRAS PROTEIN 
CAN BE PALMITOYLATED AND TRIGGER POTENT 
DIFFERENTIATION AND TRANSFORMATION 
A paper published in the Journal of Biological Chemistry^ 
Michelle A. Booden, Tara L. Baker, Patricia A. Solski, Charming J. Der, 
Steven G. Punke, and Janice E. Buss 
Abstract 
Ha-Ras undergoes post-translational modifications (including attachment 
of famesyl and palmitate) that culminate in localization of the protein to the 
plasma membrane. Because palmitate is not attached without prior farnesyl 
addition, the distinct contributions of the two lipid modifications to membrane 
attachment or biological activity have been difficult to examine. To test if 
palmitate is able to support these crucial functions on its own, novel C-terminal 
mutants of Ha-Ras were constructed, retaining the natural sites for 
palmitoylation but replacing the C-terminal residue of the CAAX signal for 
prenylation with six lysines. Both the Ext61L and ExtWT proteins were modified 
in a dynamic fashion by palmitate, without being farnesylated; bound to 
membranes modestly (40% as well as native Ha-Ras); and retained appropriate 
GTP binding properties. Ext61L caused potent transformation of NIH3T3 cells 
and, unexpectedly, an exaggerated differentiation of PC12 cells. Ext61L with the 
six lysines but lacking palmitates was inactive. Thus famesyl is not needed as a 
^Reprinted with premission of the Journal of Biological Chemistry, 1999, 274(3), 
1423-1431. 
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signal for palmitate attachment or removal, and a combination of transient 
palmitate modification and basic residues can support Ha-Ras membrane 
binding and two quite different biological functions. The roles of palmitate can 
therefore be independent of and distinct from those of famesyl. Reciprocally, if 
membrane association can be sustained largely through palmitates, famesyl is 
freed to interact with other proteins. 
Introduction 
In its GTP-bound conformation, Ha-Ras activates several signal 
transduction cascades that control gene expression and actin cytoskeleton 
organization. The most well-studied of these pathways, the Raf/mitogen-
activated protein kinase cascade-, involves a series of cytoplasmic 
serine/threonine kinases; another utilizes several members of the Rho family of 
GTP-binding proteins that regulate cell morphology. In NIH3T3 mouse 
fibroblast cells, activated forms of HRas induce mitogenesis and transformation; 
in the rat pheochromocytoma cell line, PC12, HRas activation triggers neuronal 
differentiation. More important, membrane localization of HRas is critical for 
either of these distinct biological activities. One important consequence of 
membrane binding is to enable HRas to act as a GTP-dependent, membrane-
localized docking site for effector proteins, such as Raf kinase. 
The correct targeting of Ha-Ras to the inner surface of the plasma 
membrane requires a series of post-translational modifications at the protein's C-
terminus. These reactions include attachment of the isoprenoid famesyl to a 
cysteine residue (Cys-186) located four residues from the C-terminus, followed by 
removal of the C-terminal tripeptide and methylation of the newly exposed 
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carboxyl group of the famesylated cysteine (1). The final step is palmitoylation of 
two nearby C-terminal cysteines (Cys-181 and Cys-184) (2, 3). 
The duties of these lipids has been inferred principally from mutant Ras 
proteins that lack the palmitates but retain the isoprenoid, or that lack all three 
lipids entirely. The decreased membrane binding observed with these 
modification mutants has led to the model that membrane binding is a primary 
role for the lipids attached to HRas. However, the function(s) of farnesyl and 
palmitate, individually, have not been completely elucidated. 
The consequences of famesyl attachment are particularly important because 
prenylation is the first step in processing, putting famesylation in temporal 
control of subsequent modifications. Without an isoprenoid attached to Cys-186, 
the HRas protein remains soluble, and the adjacent Cys-181 and Cys-184 do not 
become palmitoylated. An isoprenoid has been shown to be a prerequisite 
modification for recognition by both the membrane-bound protease and 
methylase enzymes which further modify the C-terminus (4, 5). It has been 
suggested that a putative palmitoyl acyltransferase may also require the presence 
of a famesyl group (6), but the authenticity of this enzymatic activity has not been 
confirmed. Famesyl thus functions in maturation of Ras proteins by acting as 
part of a signal sequence for and allowing interaction of Ras with at least two 
membrane-bound processing enzymes. 
The most well-recognized role for famesyl is its participation in Ras 
membrane binding. Prenylation is required for initiating the transition of the 
cytosolic precursor to the membrane-bound form. Whether famesyl also plays a 
role in sustaining or directing sub-membrane localization has not been clarified. 
Famesyl by itself does not confer high affinity membrane binding to Ras peptides 
in vitro (7, 8, 9) nor does it suffice for targeting of the protein to plasma 
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membranes in intact cells (10, 11, 12). The famesyl group appears to depend 
heavily on a second mechanism to assist its efforts in membrane binding. Two 
types of "secondary" membrane-binding signals have been identified: a 
hydrophobic type involving palmitoylation of nearby cysteine residues, as is 
found in Ha-Ras, N-Ras and Ki-Ras4A ; and an ionic type, based on the series of 
basic residues just N-terminal of the CAAX sequence, as found in Ki-Ras4B (2, 
13). 
A number of studies have now suggested that famesyl may have an 
additional role besides initiating membrane attachment. The famesyl group is 
proposed to bind to specific membrane proteins (14), a process that might 
enhance Ras/membrane interaction or that might be needed for activation of 
Ras effector proteins. Good evidence has been presented that a structural or 
conformational epitope found in the prenylated form of Ha-Ras is important (in 
addition to the role of Ras in Raf membrane targeting) for activation of Raf-1 
through the kinase's cysteine-rich, zinc finger domain (15, 16, 17). In vitro 
analysis has suggested that famesylation of Ha-Ras may also be needed for 
human SOSl to promote guanine nucleotide exchange (18). Earlier studies using 
an activated yeast Ras2 protein revealed that mutation of the famesylation site 
decreased the interaction between Ras2 and adenylyl cyclase (19, 20). Thus these 
studies imply that the prenyl structure of Ras may be involved in and perhaps 
required for specific associations of HRas and its regulatory or target proteins. 
How potential roles in both lipid bilayer binding and protein interactions can be 
performed simultaneously or sequentially remains an important, unanswered 
question. 
The duties for which the palmitates of Ha-Ras are used are much less 
clear. Palmitate certainly has sufficient hydrophobicity to support membrane 
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binding of an Ha-Ras protein, but the requirement for prior famesylation has 
prevented study of the role(s) of the Ha-Ras palmitates independent of 
isoprenoid. It is possible that palmitoylation of Cys-181 and Cys-184 of Ha-Ras is 
only a non-specific (although required) secondary membrane attachment signal 
that simply enables more substantial or sustained levels of membrane binding of 
a famesylated Ha-Ras. More direct, biochemical studies of palmitoylation have 
been thwarted because the enzymes that might attach palmitates to Ha-Ras, or 
similar proteins, have proved to be extremely difficult to isolate (6, 21, 22). In 
vivo requirements for palmitate attachment have been examined in a large 
series of C-terminal mutant Ha-Ras proteins, all of which became palmitoylated 
(12). These studies identified amino acids that appeared to be novel signals for 
intracellular trafficking, but no consensus sequence for palmitate attachment was 
found. However, these mutant proteins still retained an intact CAAX motif and 
were famesylated, so it remained possible that farnesyl might be part of an 
otherwise enigmatic signal for palmitoylation. Because several of these 
famesylated and palmitoylated mutant HRas proteins were mis-localized to 
internal membranes within the cell, one clear result was that acquisition of both 
C-terminal lipids is not sufficient to assure correct plasma membrane targeting. 
However, based on observations that C181S/C184S mutants of Ha-Ras 
(which retain farnesyl but lack palmitate) localize poorly to the plasma 
membrane, several studies have suggested that it is palmitate rather than 
farnesyl that is largely responsible for Ha-Ras membrane binding. In the 
Xenopus oocyte maturation assay, and also in transformation of NIH 3T3 cells, 
Ha-Ras proteins modified only by famesyl have poor biological activity, 
indicating that acquisition of palmitates is important functionally (9, 10, 11, 23, 
24). Using a yeast plasmid-loss assay, Mitchell et al. (25) studied a series of yeast 
31 
Ras2 proteins that showed that the combined effect of C-terminal basic amino 
acids and palmitoylation of cysteine residues was sufficient to support Ras-
dependent growth, independent of prenylation. More important, the biological 
function of these yeast Ras2 proteins correlated with their ability to be 
palmitoylated. These results show that palmitate is an important contributor to 
HRas membrane binding and function, and imply that, despite its chronological 
precedence, farnesyl depends upon palmitate to support these activities. 
However, it remains unclear whether palmitate mutually requires the famesyl 
or plays an independent but complementary role in specific membrane 
association and biological activity of HRas. 
To enable study of requirements for palmitate addition and to determine if 
palmitates could direct specific plasma membrane targeting, sustain Ha-Ras 
membrane binding, and support biological function, a novel mammalian Ha-
Ras protein was constructed, designed to have C-terminal palmitates but no 
isoprenoid. The results indicate that although famesyl needs the assistance of 
palmitate for membrane binding and full biological function, palmitates can 
support substantial famesyl-independent activity. The results begin to define 
distinct roles for Ha-Ras famesyl and palmitate, and suggest that palmitate is 
more than just a energetic form of membrane tether that serves the needs of the 
famesyl, and may have unique and dynamic biological roles of its own. 
Materials and Methods 
Mutants and Plasmids. Ext61L, ExtWT, Ext61L(C181S/C184S/C186S), 
ExtWT(C181S/C184S/C186S), and HRas61L were expressed from pcDNAS 
(Invitrogen, Carlsbad, CA). To construct Ext61L an S190K substitution followed 
by the addition of five lysine residues was introduced into Ha-Ras with a Q61L 
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activating mutation by oligonucleotide-directed polymerase chain 
reaction mutagenesis. The oligonucleotide 5'-GGGGGGATCCACCATGACAGA 
ATACAAGCTT-3', which was fully complementary to the 5' sequences of 
human Ha-Ras, and the mutagenic oligonucleotide 5'-GGGGGGATCCTCACTT 
CTTCTTCTTCTTCTTGAGCACACACTTGCAGCT-3 • which reproduced the 
nucleotides complementary to the 3' sequences of Ha-Ras and introduced the six 
lysine codons (underlined), a termination codon, and a BamHl restriction 
enzyme recognition site. The resulting pcDNA3-Ext61L cDNA was inserted as a 
BamHl fragment into the BamHl site of pcDNA3 and encoded the complete 
HRas protein with a C-terminal polylysine tail (Figure lA). pcDNA3-ExtWT is 
identical to pcDNA3-Ext61L, except that it encodes the non-activated cellular 
form of Ha-Ras with the normal glutamine residue at position 61. 
Ext61L(C181S/C184S/C186S) and ExtWT(C181S/C184S/C186S) were constructed 
in a similar fashion using the mutagenic oligonucleotide-5'-
GT ACTCT AGATCACTTCTTCTTCTTCTTTTTTAACACACTCTTACTGCTCATA 
GAGCCAGGACC-3' to introduce the six lysine codons (underlined) and change 
codons 181, 184, and 186 from Cys to Ser (double underlined). The cDNA was 
inserted as a BamHl-Notl fragment into pcDNA3. 
Cell culture, transfection, and transformation assays. PC12 cells were 
maintained at 5% CO2 in RPMI 1640 medium supplemented with 10% heat-
inactivated horse serum and 5% fetal calf serum (both from Hyclone 
Laboratories; Logan, UT). Twenty-four hours before DNA transfection, PC12 cells 
were plated onto laminin-coated (lO^g/ml; GIBCO-BRL; Gaithersburg, MD) 
60 mm tissue culture dishes at a density of 10^ cells/dish and grown overnight. 
Transfection was performed using LipofectAMINE reagent (GIBCO-BRL) as 
described by the manufacturer. NIH3T3 cells were grown at 10% CO2 in 
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Dulbecco's modified Eagle's medium supplemented with 10% calf serum 
(Hyclone Laboratories). Cells were transfected with plasmid DNAs encoding 
Ext61L or ExtWT Ras proteins, using the calcium phosphate precipitation 
technique(ll, 26). Transformed foci were quantified after 7-14 days. Transfected 
cells were also selected in growth medium containing G418 (Geneticin; GIBCO 
BRL) at 500|ig/ml to establish cell lines that stably expressed the mutant proteins. 
Preparation of subcellular fractions. Subcellular fractions were prepared by 
lysis of cells in hypotonic buffer (O.IM Tris, pH 7.4, 0.5M MgCl2, ImM Pefabloc, 
IpM leupeptin, 2|iM pepstatin, and 0.1% aprotinin (Calbiochem)) and addition of 
NaCl to adjust the ionic strength to 0.15 M, followed by ultracentrifugation for 30 
min at 100,000 x g as previously (26). Hydrophobic (e.g., lip id-modified) proteins 
were isolated by separation into detergent (hydrophobic) and aqueous 
(hydrophilic) fractions by Triton X-114 lysis and phase separation as described (2). 
For testing release of proteins from the PlOO membrane fraction, the supernatant 
(S100=S1) was set aside and the pellet was resuspended in 1 ml of hypotonic 
buffer supplemented with 0.5 M NaCl and incubated on ice for 30 min. The 
suspension was centrifuged at 100,000 x g; the supernatant (S2) was collected; and 
the pellet was incubated with the high salt buffer a second time and centrifuged, 
yielding a third supernatant (S3). The pellet from the second salt wash (P3) was 
resuspended in 1ml of radioimmune precipitation assay buffer and centrifuged 
and the radioimmune precipitation assay extract (S4) removed. The proteins in 
the separate S1-S4 supematants were precipitated with 10 ml of acetone for 1 h at 
4 ° C, collected by centrifugation at 3000 rpm for 30 min, and dissolved in 100 ^l 
of electrophoresis sample buffer. Equal volumes of each fraction were separated 
bySDS-PAGE. 
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Radiolabeling, Immunoprecipitation and Immunoblotting. For protein 
labeling, cells were incubated with 200 mCi/plate Tran^^S-label (ICN, Costa 
Mesa, CA) in Dulbecco's modified Eagle's medium lacking cysteine/methionine 
for 18 h. To examine isoprenoid attachment, cells were pre-treated with 50 mM 
compactin for 30 min and then labeled for 18 h with 100 mCi/mL 
[3H]mevalonolactone (ARC, St. Louis, MO) in the continued presence of 
compactin (27). Palmitate incorporation and subsequent depalmitoylation was 
measured by labeling cells for 4 h with 1 mCi/ml [^HJpalmitate (NEN Life 
Science Products) in media containing nonessential amino acids, 25 pg/ml 
cycloheximide and 10% calf serum and then incubating for varying times in 
nonradioactive media containing 200 ^M palmitic acid. After radiolabeling, 
samples were prepared for subcellular fractionation as described above, or cells 
were lysed directly in high SDS-radioimmune precipitation assay buffer (50 mM 
Tris, pH 7.0, 0.5% SDS, 1% NP-40, 1% sodium deoxycholate, 150 mM NaCl, and 
50 mM aprotinin (Calbiochem)) for immunoprecipitation. Extracts of cell 
fractions were incubated on ice for 1 hr with Ha-Ras-specific mouse monoclonal 
antibody 146-3E4 (Quality Biotech Inc., Camden, NJ). 
Immune complexes were recovered with Staphylococcus aureus cells 
(Pansorbin; Calbiochem) coated with goat anti-mouse heavy and light chain IgG; 
washed; resuspended in special sample buffer (2% SDS, 10 mM NaP04, pH 7.0, 
10% glycerol, 0.05% dithiothreitol, and 0.02% bromophenol blue); resolved by 
SDS-PAGE; transferred to polyvinylidene difluoride membrane; and, as needed, 
sprayed with EN^HANCE (NEN Life Science Products) for fluorography or 
developed for immunoblot analysis. For immunoblotting, after separation by 
SDS-PAGE, proteins were transferred electrophoretically to polyvinylidene 
difluoride membranes, and non-specific protein binding was blocked by 
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incubating the membrane in 2.5% non-fat dry milk in Tris-buffered saline. 
Membranes were probed with the Ha-Ras-specific monoclonal antibody 146-3E4. 
Biotinylated secondary antibodies (anti-mouse; Vector Laboratories, Inc., 
Burlingame, CA) were used with development by alkaline phosphatase (Vector 
Laboratories, Inc.) using the manufacturer's protocol. 
Immunofluorescence. PC12 cells were plated at low density on serum-coated 
coverslips in 6-well dishes and transfected with Ext61L DNA as described above. 
Following fixation with freshly prepared 2% paraformaldehyde, cells were 
treated with a blocking solution containing 0.4% bovine serum albumin and 3% 
horse serum to block non-specific antibody interactions and 0.05% Triton X-100 
and 0.05% Tween-20 to permeabilize the cells (28). Cells were then treated with a 
1:20 dilution of Ha-Ras-specific rat monoclonal antibody Y13-172, followed by a 
1:50 dilution of fluorescein isothiocyanate-conjugated rabbit anti-rat secondary 
antibody (Cappel/Organon-Telnicon, Durham, NC), both diluted in blocking 
solution, mounted in diazabicyclo[2.2.2]octane/glycerol solution to prevent 
fading; and viewed by corifocal microscopy. 
GTP/GDP determination. Confluent cultures of PC12 cells were grown 
over-night in 1% dialyzed calf serum. Cells were then radiolabeled with 0.5-1 
mCi/mL 32pj (NEN Life Science Products) for 4h in phosphate-free media 
containing 1% calf serum. Cells were rinsed with phosphate-buffered saline and 
lysed in 0.6 ml cold GTP lysis buffer containing 50 mM Tris-HCl, pH 7.4, 20 mM 
MgCl2, 150 mM NaCl, 0.5% (v/v) Nonidet P-40, 20 ^g/ml aprotinin, 1 mM 
EGTA, and 1 mM Na3V04. Insoluble material was removed by centrifugation at 
750 g for 3 minutes. Supematants were cleared with 50% (v/v) bovine serum 
albvunin-coated charcoal in lysis buffer, and then Ha-Ras proteins were captured 
by immunoprecipitation using GTP lysis buffer. Ha-Ras and its bound 
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nucleotides were eluted by heating to 60 ° C for 5 minutes in a minimal volume 
of buffer containing 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 2% (w/v) SDS, 2 mM 
GDP, and 2 mM GTP. The eluants were cleared by centrifugation at 10,000 x g for 
5 min, and then samples were spotted on polyethyleneimine cellulose plates (J.T. 
Baker, Inc,) and separated with 0.75 M KH2PO4, pH 3.4. Plates were dried and 
exposed to pre-flashed film using screen enhancers. The film images of GDP and 
GTP were scarmed and quantified using the program ImageQuant (Molecular 
Dynamics, Inc.) and the percent of an Ha-Ras protein that contained bound GTP 
was calculated using the following formula: % with GTP = GTP/(GTP + (1.5 
GDP). 
Results 
Ext61L cDNA produces a stable protein that is not prenylated. Multiple 
studies which had examined a great many mutations within and immediately 
N-terminal of the CAAX box of non-prenylated Ha-Ras or Ki-Ras4B proteins had 
all failed to detect membrane binding (a biochemical surrogate for potential 
palmitoylation). The only successful examples of palmitoylated forms that 
lacked isoprenoid were the yeast Ras2 mutants in which the CAAX box was 
extended with a series of basic amino acid residues (25). This work had suggested 
that lengthening and introducing positively charged residues enabled a yeast 
Ras2 protein to contact membranes and to become palmitoylated. The 
mammalian ExtRas proteins were therefore designed with a lysine in the X 
position of the CAAX box, which was anticipated would produce a non­
functional prenylation motif, and five additional lysine residues to provide an 
ionic platform for interaction with acidic membrane phospholipids. 
37 
The initial experiments determined the stability and size of the Ext61L 
protein and whether the carboxyl-terminal CVLKKKKKK sequence (Fig. lA) 
prevented the Ext61L protein from being prenylated. This was important because 
it was possible the Ext61L protein would be vulnerable to proteolytic removal of 
these basic residues, which would remove the structure that was meant to 
initiate and assist membrane binding. Also, removal of five lysines would 
potentially create a CAAX box motif (CVLK) that might permit prenylation. This 
was not considered likely as the presence of a lysine at the X position had 
previously been found to prevent prenylation of a Ki-Ras-4B protein (29). If such 
trimming and prenylation were to occur, it could be detected because it would 
produce a smaller protein, similar in size to mature, native HRas protein. An 
additional way to detect, indirectly, if prenylation was occurring was to treat cells 
with compactin. Compactin inhibits isoprenoid synthesis and hence decreases 
Ras prenylation, preventing the change in mobility and leading to the 
accumulation of the urunodified precursor form of Ha-Ras in the cytosol (1). 
To test these possibilities, COS cells expressing Ext61L were labeled 
metabolically with [35s]methionine in the presence or absence of compactin. 
Cytosolic and membrane-containing fractions were prepared, and proteins were 
separated by SDS-PAGE, and detected by fluorography. The Ext61L protein was 
easily detected and had the appropriate, slightly slower mobility than the 
endogenous Ha-Ras protein of COS cells, indicating that the C-terminal residues 
of Ext61L were retained (Fig. IB). More important, a significant portion (40%) of 
the Ext61L protein was detected in the membrane-containing fraction and had 
the same apparent size as the cytosolic protein. This similarity in size of proteins 
in the SlOO and PlOO fractions indicated indirectly that the extension protein was 
not famesylated. In addition, compactin did not decrease the amount of Ext61L 
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protein that was present in the PlOO fraction. Without compactin treatment, 
>90% of the small amount of endogenous HRas protein in untransfected or 
transfected COS cells (Fig. IB) was found in the membrane fraction. In the 
compactin-treated cells the amount of membrane-bound endogenous HRas 
decreased; the increased amount of the precursor form in the cytosol was 
obscured by the large amount of soluble Ext61L protein. 
To evaluate more directly whether the Ext61L protein remained 
unmodified by isoprenoid, COS cells expressing this protein or Ha-Ras61L were 
labeled with [^HJmevalonic acid and the Ras proteins were isolated by 
immunoprecipitation. No incorporation of radioactivity could be detected in the 
Ext61L lane (Fig. IC, lane 2). However, labeling of cells expressing Ha-Ras61L 
confirmed that an Ha-Ras with an intact CAAX motif could be prenylated (Fig. 
IC, lane I). In addition, immunoblot detection of the same membrane 
confirmed that the Ext61L protein was expressed (data not shown). These results 
indicated that the Ext61L protein was not prenylated. 
Ext61L binds membranes rapidly and is targeted to the plasma membrane. 
Although a significant amount of Ext61L protein was found in the membrane-
containing fraction in the cells, the extent of binding of the Ext61L protein was far 
less than the >95% binding attained by endogenous Ha-Ras with the natural 
version of the C-terminus. Previously constructed C-terminal mutants of v-Ha-
Ras had also shown decreased or delayed membrane binding compared to v-Ha-
Ras with the normal C-terminal residues and modifications (11). To examine if 
the decreased membrane association of Ext61L reflected inefficient trafficking or 
attachment to membranes, the speed with which newly synthesized Ext61L 
traversed the cytosol and achieved membrane association was assessed. 
Replicate dishes of cells were metabolically labeled with 
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[35s]methionine/cysteine for 10 min, and then one plate was incubated in non­
radioactive medium for an additional 30 minutes. Subcellular fractionations 
were prepared, and Ha-Ras immunoprecipitates were formed. Within the 10-
min pulse period 27% of the newly synthesized Ext61L protein had already 
translocated to the membrane (Fig. 2A). After t30-min chase, the Ext61L in the 
membrane-containing fraction had increased to 44% of the total protein, and 
therefore to the same level seen at steady state. This speed of membrane binding 
was similar to or even faster than that seen with a v-Ha-Ras protein that 
undergoes both famesylation and palmitoylation (11). The addition of the basic 
residues to Ext61L therefore did not impede normal trafficking or delay 
membrane attachment. 
Some of the previously mentioned v-Ha-Ras C-terminal mutants, which 
by biochemical fractionation techniques were membrane-associated, were 
subsequently found to be mis-localized to internal rather than plasma 
membranes (11). This intracellular trapping was correlated with poor biological 
activity. As a more definitive way to assess attachment to specific membranes, 
immunofluorescence was used to visualize the subcellular localization of Ext61L 
in intact, single cells. A series of confocal laser microscopic images of PC12 cells 
expressing Ext61L exhibited a clear defined signal of Ext61L at the plasma 
membrane (Fig. 2B). No staining of internal membranes was observed. These 
data, taken together with the biochemical data described above, indicated that 
somewhat less than half of the Ext61L protein succeeded in associating with 
membranes and more specifically, that these membrane-bound molecules were 
located at the plasma membrane. 
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Ext61L associates with membranes largely through hydrophobic 
interactions. The lysines at the terminus of ExtRas were envisioned to 
participate in ionic interactions with acidic phospholipids of the plasma 
membrane and thus to initiate membrane binding that would enable 
palmitoylation. To determine if ionic forces might also contribute to 
maintenance of the association between the Ext61L protein and cellular 
membranes, addition of a concentrated salt solution to isolated membranes was 
used to disrupt ionic interactions (2). Membranes from transfected COS cells 
were first separated from the cytosol, suspended in 0.5 M NaCl for 60 minutes 
and then again isolated by sedimentation. Less than 10% of the membrane-
associated Ext61L protein was released by the salt extraction procedure (S2) (Fig. 
3A). The basic residues of Ext61L thus appeared to contribute in only a small 
way to long-term stability of membrane association. 
Because ionic forces could not account for the substantial amount of 
protein that partitioned into the P-100 fraction at steady state, the ability of 
detergent to extract the membrane-bound Ext61L protein was used to further 
explore if the portion of Ext61L that resisted salt wash-out was bound to 
membrane through hydrophobic forces. The salt-washed membranes were again 
washed with 0.5 M NaCl (S3) and then resuspended in SDS-containing buffer. 
The detergent-released material (S4) was separated from the residual detergent-
insoluble material by centrifugation. For Ext61L, -75% of the membrane-
associated protein was released after SDS extraction (S4) (Fig. 3A). The 
palmitoylated and famesylated endogenous Ha-Ras prptein in untransfected COS 
cells resisted the salt wash-out and was released by detergent in the S4 fraction. 
To further determine if the Ext61L protein displayed any hydrophobic 
character suggestive of a lipid modification, transfected cells were also processed 
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by Triton X-114 phase separation. This procedure separates cellular proteins 
based on overall hydrophobic character, into either an aqueous (hydrophilic) or 
detergent (hydrophobic) fraction. For the Ha-Ras protein, whose amino acid 
sequence is hydrophilic, Triton X-114 phase separation has been used to 
distinguish forms that have or that lack lipids. Cytosolic (S-100) and membrane-
containing (P-100) fractions were prepared from PC12 cells expressing Ha-Ras61L 
or Ext61L proteins. The membranes were further partitioned by resuspending 
the P-100 fraction in 1% Triton X-114 and warming the sample to trigger phase 
separation. For the Ha-Ras61L protein, with the native version of the C-
terminus, the precursor form (not yet lipid modified) was present in the cytosol, 
whereas the mature Ha-Ras61L protein (farnesylated and palmitoylated) 
appeared in the detergent phase (Fig, 3B). For Ext61L, -60% of the protein again 
was cytosolic, and roughly half of the -40% of the protein that sedimented in the 
PlOO fraction (in multiple experiments, varying from 15 to 25% of the total 
protein) further partitioned into the detergent phase, suggesting that this minor 
portion of the expressed protein possessed hydrophobic character (Fig. 3B). 
The Ext61L protein is palmitoylated. The two cysteines (Cys-181 and Cys-
184) that are palmitoylated in the Ha-Ras 61L protein are retained in Ext61L, as is 
Cys-186, which is normally modified by famesyl. Thus, the Ext61L protein has 
three potential sites for palmitate attachment. To determine whether or not 
Ext61L was palmitoylated, NIH 3T3 cells expressing Ext61L and 61L, respectively, 
were labeled for 3 hours with [^HJpalmitate, followed by a chase in non­
radioactive medium. At the indicated times, immunoprecipitates were formed, 
and palmitate labeling of the Ext61L and 61L proteins was detected by 
fluorography. The Ext61L protein not only incorporated palmitate, but did so at a 
rate similar to the 61L protein; both required ~3h for maximum [^H] palmitate 
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labeling (data not shown). During the chase, the depalmitoylation rates for the 
two proteins were also similar (Fig. 4). When immunob lotting was used to 
account for variations in Ras protein recovery in the samples on the membrane 
(data not shown) both Ext61L and 61L lost half of their incorporated palmitate 
between 2 and 4 hours . Similar results were also obtained using PC12 cells 
transiently expressing either Ext61L or 61L (data not shown). The palmitoylated 
form of the Ext61L protein was detected only in the membrane-containing 
cellular fraction, with no evidence of a partially (de)palmitoylated protein being 
released into the cytosol (MAB, preliminary results). Thus, although the Ext61L 
protein was not prenylated, it could be palmitoylated, and the palmitate 
displayed an apparently normal turnover rate. This indicated that the presence 
of the polybasic domain did not prevent the Ext61L protein from being accessible 
to either acylating or deacylating enzymes. 
Ext61L transforms NIH 3T3 cells. Soluble Ha-Ras61L protein has been 
reported to act as a dominant negative inhibitor of Ha-Ras transformation of 
NIH 3T3 cells (30,31), presumably by binding and trapping effector proteins, such 
as the Raf-1 protein kinase, in the cytosol. Because a large amount of Ext61L was 
cytosolic it was possible that the biological effectiveness of Ext61L would be 
dampened by this pool of cytosolic protein. The ability of the Ext61L protein to 
stimulate mitogenesis and transformation of NIH3T3 cells was examined to 
ascertain if the combination of palmitate and basic residues was capable of 
supporting a biological function of Ha-Ras. Ext61L DNA was potently 
transforming, and caused robust focus formation (-1100 foci/|ig of DNA) (Table 
1). This activity was equivalent to the transforming activity of DNA encoding 
the Ha-Ras61L form with the native lipid modifications. The cellular version of 
the ExtRas protein, ExtWT, did not cause focus formation in NIH 3T3 cells, even 
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when the cells were transfected with up to 2 ^ig of DNA. This lack of activity was 
similar to the low tranforming activity of the normally lipidated form of Ha-Ras, 
p21WT. The morphology of transfected NIH 3T3 cells expressing Ext61L was 
easily distinguished from that of cells expressing the normally lipidated 61L 
protein: foci produced by 61L were typically swirling, spreading colonies of 
transformed cells, whereas the Ext61L-induced foci contained clumps of cells that 
tended to round up and pull away from the plastic substratum, and contained 
unusually long, spindle-shaped, elongated cells with a refractile appearance (data 
not shown). 
To determine if Ext61L expression also triggered anchorage-independent 
growth, NIH 3T3 cells stably expressing Ha-Ras61L or Ext61L were plated in soft 
agar and assayed for the ability to form colonies. Like Ha-Ras61L-transformed 
cells, Ext61L-transformed cells readily formed colonies in soft agar (data not 
shown). All together, these results demonstrated that the non-prenylated but 
palmitoylated Ext61L protein produced the aberrant growth properties 
characteristic of an oncogenic HRas protein in NIH 3T3 cells. 
Ext61L causes neurite extension in PC12 cells. Transformation of NIH 3T3 
cells is a hallmark of oncogenic HRas activity that culminates in focus formation. 
To assess a different aspect of Ras biological function, the ability of the Ext61L 
protein to cause differentiation of PC12 cells was examined. In PC12 cells 
expression of activated Ras proteins is characterized by the cessation of mitosis, 
unique rearrangements of the actin cytoskeleton and extension of neuron-like 
processes, in a program of events similar to those triggered by exposure to nerve 
growth factor (32, 33). OrUy activated forms of Ras have been found to produce 
this response, whereas normal, cellular Ras has no effect (34, 35, 36). More 
important, Ras must be membrane-bound to cause neurite extension, as non-
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lipidated forms, even if activated, are incapable of triggering differentiation (37, 
38). 
PC12 cells transfected with DMA encoding a cellular, normally lipidated 
form of HRas (p21WT) continued to proliferate and showed the limited 
adherence and round shape characteristic of the parental PC12 cells (Fig. 5a and 
b). PC12 cells transfected with DNA encoding the constitutively active, 
prenylated and palmitoylated Ha-Ras61L protein developed neurites that 
attained a length of greater than two cell bodies after ~48 h (see Fig. 5 legend). 
There were two or occasionally three of these axon-like extensions/cell, which 
continued to elongate over the next 2-3 days. However, at 48hrs only 21% of 
these extensions were longer than 100 jim (see Fig. 5 legend). The processes were 
smooth and, during the first days, generally extended linearly, with a single 
growth cone on each and little branching (Fig. 5e). The amount of DNA 
necessary to generate this rate and extent of response by Ha-Ras61L was titrated 
and found to require 1 )ig of DNA. The morphology of PC12 cells expressing Ha-
Ras61L was similar to that of the cells treated with 50 ng/ml nerve growth factor, 
although the nerve growth factor response required 2-3 days for neurite 
extension to be established, and progressed more slowly, over 8-10 days (data not 
shown). 
In contrast, PC12 cells transfected with 1 pg of DNA encoding the Ext61L 
protein developed multitudes of neurites (Fig. 2B). As little as 50 ng of DNA 
encoding the Ext61L protein caused development of visible neurites as early as 
24 h after transfection (Fig. 5f). These processes were longer than those produced 
by 61L, and extended rapidly, exceeding within 2 days even the final length of 
those in the 61L cultures (Fig. 5e). Cells expressing the Ext61L protein often 
produced four or five extensions/cell and 84% of these extensions were longer 
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than 100 jam 48 hrs after transfection (see Fig. 5 legend). Furthermore, as the 
differentiation of these cells progressed, the extensions became highly branched, 
wandered in several directions, and displayed numerous fine filopodia along 
their length. In addition, Ext61L brought about a flattening of the cell body, with 
large lamellipodia, areas of adherence, and veils of attachment. A prominent 
feature of cells expressing the Ext61L protein was the accumulation of numerous 
large, intracellular vesicles. The biological activity of Ext61L was therefore 
unexpectedly robust, and the morphological changes it caused were an 
exaggerated version of those caused by the normally lipidated 61L protein. 
To determine if the conspicuous activity of Ext61L could be ascribed to 
particularly efficient protein expression, the amount of Ext61L or Ha-Ras61L in 
the membrane/detergent fraction prepared from differentiated PC12 cells 
transfected as described for Fig. 5 was examined more closely. In the Ext61L-
expressing cells, the amount of protein in the detergent fraction was less than the 
amount present in the detergent fraction of the Ha-Ras61L-expressing cells (Fig. 
36). However, despite expressing smaller amounts of membrane-associated 
protein, the culture transfected with Ext61L DNA exhibited more extravagant 
neurite extensions than the parallel culture of cells expressing 61L protein (Fig. 
5e and /). Additional experiments using an even smaller amount of Ext61L DNA 
(10 ng) showed that exaggerated neurite morphology was still produced when the 
total amount of Ext61L protein (cytosolic + aqueous + detergent) was much less 
(approximately one-tenth) than the total amount of protein that was present in 
the parallel culture transfected with 61L DNA (data not shown). Thus, even 
with smaller amounts of membrane-bound protein, Ext61L continued to exceed 
61L activity and to display unusual characteristics in the neurites it produced. 
Therefore, in two assays that test quite different outcomes of Ha-Ras activity. 
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transformation and differentiation, there was certainly no evidence that the 
residues appended to the C-terminus or the large amount of cytosolic Ext61L 
protein diminished biological function. 
The cellular form of the extension protein, ExtWT, causes differentiation 
of PC12 cells. The unusual activity of the Ext61L protein in PC12 ceils raised the 
possibility that the cellular (wild-type) form of ExtRas might generate a response 
in PC12 cells. Transfection of PC12 cells with as little as 250 ng of ExtWT DNA 
caused production of neurites, with an accelerated time course that was 
intermediate between that of Ha-Ras61L and Ext61L and with a morphology 
characteristic of and as unusual as the Ext61L protein (Fig.. 5g). This amount of 
ExtWT DNA caused production of protein amounts that were less than those 
produced in parallel cultures expressing Ha-Ras61L protein (data not shown). 
The quite appreciable activity of the ExtWT protein contrasted with the complete 
inactivity of normal Ha-Ras with the native C-terminal residues and lipid 
modifications. Transfection of cultures with 40-times larger amounts of DNA 
(10 )ig) for p21WT produced abundant protein expression (data not shown), but 
caused no neurite extension (Fig. 5b) (36). Thus, these changes in the Ha-Ras C-
terminus appeared to have also increased the biological activity of a cellular form 
of Ha-Ras to cause PC12 cell differentiation. 
Palmitoylation is required for ExtRas mediated differentiation of PC12 cells 
and membrane localization. Previous observations have established that 
prenylation and either palmitoylation or a stretch of basic amino acids are 
required for membrane localization and biological activity of Ras proteins (2, 20). 
To determine if the exaggerated activity of Ext61L could be ascribed to the 
polylysine motif, ExtRas proteins that could not be palmitoylated 
(Ext61L(C181S/C184S/C186S) and ExtWT(C181S/C184S/C186S)l were constructed. 
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The C181S/C184S/C186S mutants were unable to induce differentiation of PC12 
cells (Fig. 5c and d). Thus, the C-terminal polylysine motif, without palmitate, 
did not support Ha-Ras biological activity. 
The subcellular localization of Ext61L and ExtWT(C181S/C184S/C186S) was 
also examined by subcellular fractionation with Triton X-114 phase separation. 
As shown in Fig. 3, the ExtRas (C181S/C184S/C186S) proteins, which lack 
palmitates but retain the lysines, were localized completely to the cytoplasm . 
Thus, the polylysines alone were not sufficient to maintain association of 
ExtRas(C181S/C184S/C186S) with the plasma membrane, and stable membrane 
attachment of ExtRas appeared to require palmitoylation. 
Ext 61L and ExtWT bind GTP/GDP appropriately. One possible 
explanation for the pronounced activity of the ExtWT and Ext61L proteins was 
that the changes at the C-terminus altered access of nucleotide exchange proteins 
or GTPase-activating proteins which regulate the ability of Ha-Ras to bind GTP 
and allowed the accumulation of the active form of these proteins, especially 
ExtWT. To test if the levels of GTP bound to ExtRas proteins were elevated, 
transfected PC12 cells were labeled with 32pi and radioactive nucleotides bound 
to Ha-Ras immunoprecipitates were separated by thin-layer chromatography. In 
differentiated PC12 cells, 83% of the expressed 61L protein and 82% of the Ext61L 
protein were in the GTP-bound form (Fig. 6). In a second experiment, 
nucleotides bound to cytosolic and membrane-associated forms of the proteins 
were analyzed. The portion of the membrane-bound form of Ext61L that had 
GTP (82%) was the same as the portion that bound GTP in the cytosolic form 
(data not shown), suggesting that GTPase-activating proteins were equally 
(in)effective on the Ext61L protein in either location. Thus both the soluble and 
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membrane-bound forms of Ext61L were, to an extent similar to Ha-Ras61L, 
predominantly in the active conformation. 
For the ExtWT protein, 8% of the protein contained GTP (Fig. 6). This is 
equivalent to the portion found using this isolation protocol on an 
overexpressed, cellular Ha-RasWT in NIH 3T3 cell lines, where 8% was also in 
the GTP-bound form (data not shown). Again, both cytosolic and membrane-
associated ExtWT proteins appeared to have similar GTP/GDP ratios (data not 
shown). Thus the ExtWT protein was primarily in the GDP state, as appropriate 
for a cellular form of Ha-Ras, and showed no evidence that the altered C-
terminus had increased interactions with exchange factors or decreased 
interactions with GTPase-activating protein(s) to the point that could explain its 
potent differentiating activity. 
Discussion 
Targeting and stable localization of Ha-Ras to the plasma membrane 
coincides with acquisition of biological activity. However, the possibility of 
distinct or independent contributions of the two lipid modifications to targeting, 
binding, or function has been difficult to examine. We have developed a unique 
form of Ha-Ras that can be palmitoylated without the requirement for prior 
famesylation. The C-terminal changes in this protein do not appear to have 
altered the basic GTP binding properties of this protein and the protein causes 
unexpectedly potent biological function of two quite different types. These 
studies support the possibility that palmitate may have structural and biological 
roles of its own, independent of isoprenoid. 
Requirements for palmitate attachment and removal. To produce a 
palmitoylated but non-prenylated protein, an artificial polylysine domain was 
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attached to the C-tenninus of Ha-Ras. The polylysine tail was designed to be (and 
was apparently successful as) an ionic platform through which the otherwise 
soluble, non-prenylated Ha-Ras protein could initiate membrane contact and 
undergo subsequent palmitoylation, which then promoted tighter and more 
sustained interaction. This tail motif partially mimics the larger polybasic region 
found just internal to the carboxy terminus of the Ki-Ras4B protein, which has 
no cysteines that can be palmitoylated. However, in Ki-Ras4B the simple 
presence of a C-terminal polybasic domain, without famesylation, does not 
support membrane-binding (2, 29, 39, 40). 
The ExtRas proteins share several properties with a non-famesylated 
mutant yeast Ras2 protein with the C-terminal sequence CCIIKLIKRK (mutated 
CAAX box underlined). This mutant Ras2 protein is also palmitoylated (at the 
cysteine previously used for famesyl attachment as well as the natural adjacent 
site), binds membranes, and is biologically functional (25). Why having a series 
of positively charged residues beyond the natural C-terminal end of Ha-Ras or 
Ras2 might permit palmitoylation remains to be studied, but this placement does 
appear to be a successful method to circumvent the need for prenylation and to 
permit palmitate attachment, and may be applicable to other proteins as well. 
The data presented here demonstrate that Ha-Ras can be palmitoylated at 
the natural C-terminal sites without being famesylated. Our own studies have 
indicated that palmitoylation of Ha-Ras, although proposed to be catalyzed 
enzymatically, has no discernible primary amino acid structure that functions as 
a potential signal sequence (11). The successful palmitoylation of the non-
prenylated Ext61L protein clearly indicates that a famesyl is not a required part of 
a recognition motif for any potential Ha-Ras acyltransferases. 
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A dynamic balance of addition and removal is a central property of Ha-Ras 
palmitate modification and the characteristic that most clearly differentiates it 
from prenylation. The Ext61L protein has three cysteines that are potential sites 
for palmitoylation. Whether all of these sites are used or to what extent each is 
modified is unknown, as current methods to directly examine palmitate 
stoichiometry are unsatisfactory. The abundant amount of cytosolic Ext61L 
protein indicates that palmitoylation of this protein is less complete than that of 
the native form. The polylysine extension on Ext61L is compatible with 
dynamic, transient acylation-deacylation and does not prevent access of 
thioesterases to the C-terminus. Future studies can now be designed to remove 
lysine residues and to replace each cysteine individually to more clearly define 
favored sites for palmitate attachment as well as the requirements for palmitate 
removal. 
Properties needed for membrane interaction. For Ha-Ras, famesyl is a 
rather poor membrane tether; only about 10% of the protein is membrane-
bound when a famesyl is the only lipid present (2, 11). With only palmitate and 
lysines present, Ext61L interacts with membranes to a greater extent than Ha-
Ras(C186S), a property presumably due to the combination of hydrophobic and 
ionic signals in Ext61L. However, the sizeable pool of cytoplasmic Ext61L protein, 
which has the lysines but no palmitates, suggests that the lysine residues on their 
own do not contribute greatly to long-term membrane interactions. The 
solubility of the mutant Ext61L(C181S/C184S/C186S) supports this inference, as 
does the yeast Ras2-extension protein, where mutation of the cysteines to serines, 
leaving the polybasic residues intact, abolishes membrane interaction (25). These 
results argue that firm membrane interaction of an Ha-Ras protein does not 
require a permanently attached lipid and that it is largely the palmitates, despite 
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their continuous cycles of attachment and removal, that support the stable 
interaction of the Ext61L protein with membranes. This capacity of palmitates 
has not previously been demonstrated. Thus, if palmitates can assume 
responsibility for bilayer interactions, famesyl does not need to be permanently 
engaged in this function and becomes available for additional interactions with 
proteins within the membrane or with effectors. These results emphasize that 
palmitate and farnesyl may have distinct, perhaps sequential, but 
complementary roles in membrane binding and function of Ha-Ras. 
However, the combination of palmitates and lysines clearly is not as 
efficient as the >95% achieved by the natural farnesyl plus palmitate 
modification. One possible explaination for this modest amount of membrane-
bound Ext61L protein is that, in the absence of a tethering famesyl, the dynamic 
turnover of the palmitates now sets a new, lower equilibrium point for 
membrane attachment/release. The amount of membrane-bound ExtRas is 
likely to depend heavily on the rates of palmitoylation and deacylation. The 
development of the ExtRas proteins should now allow events that may regulate 
Ha-Ras palmitoylation and membrane interactions to be addressed more clearly. 
Other C-terminal alterations in HRas have produced proteins that are 
located on intracellular, possibly Golgi, membranes (II). Such data suggest that 
unexplored determinants of plasma membrane targeting are located in the C-
terminus of Ha-Ras, and may include the sites of palmitoylation. That region 
remains unaltered in the Ext61L protein, and may continue to impart specific 
plasma membrane interaction signals because immunofluorescence showed 
strong plasma membrane localization and no staining of internal membranes. 
Additional studies can now determine if the GTP-bound Ext61L and GDP-bound 
ExtWT proteins are associated with membrane subdomains (e.g., "rafts" or 
52 
caveolae) and how their localization compares with that Ha-Ras protein with the 
natural lipid modifications. The ExtRas proteins will permit study of the specific 
roles of palmitate and famesyl in this compartmentation. 
Influence of the HRas C-terminus on biological function. Early studies 
had suggested that the C-terminal lipids on Ras proteins were only a convenient 
method for membrane attachment, were not required for more specific 
interactions with membrane or effector proteins, and were therefore only 
indirectly involved in signal transduction. This inference was based on studies 
in which leader sequences (N-myristoylation or an actual transmembrane 
domain (41) were used to target non-famesylated Ha-Ras(C186S) proteins to the 
plasma membrane. Such chimeric proteins possessed quite good activity in 
transformation of NIH 3T3 cells, demonstrating that the biological function of 
transformation did not specifically need famesyl. However, one group reported 
that the membrane binding provided by the N-myristoyl group re-established 
palmitoylation of the two C-terminal Cys-181 and Cys-184 residues (23). That 
finding remains unconfirmed, as conflicting results have been reported (11), but 
is potentially important because it implies that acylation may have a direct 
impact on biological function. 
Two additional observations have also implicated the C-terminal lipids in 
roles beyond membrane anchoring. First, N-myristoylation of a cellular form of 
non-prenylated Ha-Ras(C186S) potentiated the low transfoming activity of the 
normal protein almost 1000-fold (26). This implies that this particular N-
terminal surrogate membrane targeting system releases cellular Ha-Ras from a 
restraint that usually keeps such oncogenic activity in check. 
Second, some studies have inferred that Ha-Ras lipids, particularly 
famesyl, interact directly with proteins, rather than, or in addition to, a 
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membrane bilayer. A famesyl has recently been reported to be required for 
interaction of Ha-Ras with a plasma membrane protein (14). A farnesyl-
dependent interaction between Ha-Ras and the zinc finger (cysteine-rich domain) 
of Raf-1 kinase has also been suggested to occur (15, 42). In these instances, the 
non-famesylated forms that were used also lacked palmitate, so the contribution 
or requirement of the acyl group to these interactions remains to be answered. In 
the yeast Ras2 protein, famesyl, but not palmitate, is reported to be required for 
Ras-mediated signal transduction, where it plays an essential, possibly direct role 
in promoting protein-protein interactions between yeast Ras and a regulatory 
protein of adenylyl cyclase, its downstream effector (20). All these results imply 
that both C-terminal lipids may have important roles in Ha-Ras effector 
interaction and function that await exploration. 
The strong differentiating and transforming activity of Ext61L was 
somewhat surprising because previous studies had found that mutant Ras 
proteins that were poorly membrane bound were also poorly transforming (10, 
11). The potency of Ext61L could not be explained by abnormally stable 
palmitoylation of the membrane-bound form or by a greater amount of protein 
in membranes. Even when lesser amounts of membrane-associated protein 
were present, Ext61L still caused a more rapid and exceptional differentiation of 
PC12 cells than 61L protein. The morphology of NIH 3T3 cells expressing Ext61L 
is also distinguishable from that of cells expressing authentic 61L. These unusual 
morphologies suggests that cytoskeletal pathways are perturbed. Studies are 
underway to determine if Ext61L interacts with and activates the same pathways 
as 61L with the native C terminus and lipids or if the introduction of the basic 
residues has altered or added effector proteins to the repertoire of Ha-Ras 
partners. The change in lipidation of the Ext61L protein may also irifluence the 
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(sub)membrane localization of the protein and thus indirectly affect its access to 
regulatory or effector proteins. 
The possibility that interactions with effectors or membranes may have 
been changed in the ExtRas proteins is supported by the unexpected activity of 
ExtWT . Non-activated or wild-type forms of Ha-Ras do not normally induce 
differentiation of PC12 cells (34, 43), yet the ExtWT protein produced robust 
neurite extension. More important, the vigorous biological activity of the 
ExtWT protein in PC12 cells did not seem to be caused by decreased GTPase 
activity or altered interactions with GEFs or GTPase activating proteins, which 
regulate Ha-Ras/GTP binding, as the ExtWT protein was GDP-bound to the same 
extent as the normal cellular form. 
The ExtRas proteins appear to be a new type of activated Ha-Ras because 
activation has occurred 1) by a mechanism that does not involve changes in GTP 
binding or hydrolysis and 2) through alteration of a domain previously not 
considered to be directly involved in signal transduction. The exaggerated 
activity of the Ext61L protein further emphasizes that mutation of the C-
terminus can have a direct (stimulatory) effect on two types of HRas biological 
activity. These results suggest an expanded model for Ras activation: that 
functional interactions of the ExtRas proteins may be controlled, in addition to 
the GTP-sensitive switch regions of the protein, by the C-terminal domain. 
Studies with the ExtRas proteins will be valuable for determining how this 
activation arises and if Ha-Ras with its natural lipid modifications also utilizes 
the C-terminal domain and its attached lipids in an active role in Ras-mediated 
signal transduction. 
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Table 1. Transfonnation of NIH 3T3 cells by ExtRas proteins. 
''DNA transfected average # foci^ /mg DNA 
Ext61L 1438 
ExtWT 1 
61L 1508 
WT p21ras 2 
''Each DNA was ligated into the expression vector pcDNA3 and introduced into 
NIH3T3 cells using the calcium phosphate transfection technique. Amounts of 
DNA used were varied from 20 to 100 ng/plate for the Ext61L and 61L constructs; 
ExtWT and p21WT DMAs were tested at 500, 1000, and 2000 ng/plate. 
i. 
Foci of transformed cells were counted after 10-14 days. Experiments with Ext61L 
and ExtWT were repeated four separate times. Data shown are the averages of 
the number of foci counted, normalized to represent 1 p.g of DNA. 
Figure 1. Post-translational processing of Ext61L. 
A. Amino acid sequences of the C-terminus of H-Ras 61L and Ext61L proteins. 
B. NIH3T3 cells transfected with Ext61L or empty vector, were metabolically 
labeled with [^^S] methionine/cysteine for 18 h in the presence or absence of 
50 ^M compactin. The cell lysate was then separated into crude soluble (S) 
and particulate (P) fractions. Labeled proteins were immunoprecipitated from 
each fraction, resolved by SDS-PAGE, and detected by fluorography. 
Endogenous HRas proteins are indicated by the arrowhead (^). 
C. Parallel cultures of COS cells expressing HRas61L (lane 1) or Ext61L (lane 2) 
were metabolically labeled with [3h]MVA for 18 hrs in the presence of 50 ]IM 
compactin. Immunoprecipitates were resolved by SDS-PAGE, transferred to 
PVDF membrane and radiolabel detected by fluorographic exposure for 14 
days. 
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Carboxy-terminal extension to HRas 
HRas 180GCMSCLCVLS 
ExtRas 180GCMSCLCVLKKKKKK 
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Figure 2. Ext61L binds membranes rapidly and is located on plasma membranes 
of PC12 cells. 
A. COSl cells transfected with empty vector (Mock) or expressing Ext61L protein 
were labeled with [^^S] methionine/cysteine for 10 minutes then either lysed 
immediately (0 minute chase) or incubated in non-radioactive media for an 
additional 30 minutes. The resulting lysates were separated into soluble (S) 
and particulate (P) fractions, immunoprecipitates formed with HRas antibody, 
and proteins resolved by SDS-PAGE. Labeled proteins were detected by 
fluorography. The culture used to prepare the sample for the 30' chase point 
for Ext61L had fewer cells present than the cultures used for the 0' points. An 
arrowhead (^) designates endogenous HRas; the arrow indicates the Ext61L 
protein. 
B. PC12 cells were plated on serum-coated coverslips and transfected with 1 |ig 
Ext61L DNA. After 2 days, the cells were fixed and permeabilized, then 
treated with Y13-172 anti-Ras monoclonal antibody and FITC-conjugated 
secondary antibody. Cells were viewed by confocal fluorescence microscopy. 
Scale bar is 40 |jm. Displayed is a representative cell with multiple membrane 
projections and outgrowths frequently observed in PC12 cells expressing 
Ext61L. More than 100 cells which possessed neurite extensions were 
surveyed and all possessed similar plasma membrane-specific distribution of 
Ext61L. The signal from endogenous HRas in untransfected cells was too low 
to be detected (See Fig. 5a for morphology). 
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Figure 3. Ionic and hydrophobic contributions to membrane binding of Ext61L. 
A. Non-transfected and transfected COS cells were separated into crude soluble 
(SI) and particulate fractions. Particulate proteins were further separated by 2 
sequential incubations in 0.5M NaCl and centrifugation to generate salt-
released proteins (S2 and S3). Proteins which were not released by the salt 
washes were extracted by suspension in a buffer containing SDS and NP-40 
and separated a final time into detergent-soluble (S4) and insoluble (P4, not 
shown) fractions. HRas proteins were immunoprecipitated from each 
fraction, resolved by SDS-PAGE, and detected by immunoblotting. An 
arrowhead (^) designates endogenous HRas. 
B. At 4 days post-transfection, PC12 cells transfected with either 1 ^ g HRas61L, 50 
ng Ext61L, 1 Jig Ext61L(3S), or 1 jig ExtWT(3S) DNA, were separated into 
cytosolic (S) and particulate (P) fractions. The (P) fraction was further 
subjected to Triton X-114 partitioning. All fractions were precipitated in cold 
acetone, resuspended in 100 mL electrophoresis sample buffer and equal 
portions of cytosolic (S), aqueous (A), or detergent (D) phase resolved by SDS-
PAGE. HRas proteins were detected by immunoblotting . Ext61L is indicated 
by the arrow. An arrowhead (^) marks the mature form of 61L in the D 
fraction and an asterisk (*) marks the precursor form of 61L in the S fraction. 
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Figure 4. Ext61L is palmitoylated and displays normal palmitate turnover rates. 
G418-selected NIH3T3 cell lines expressing either HRas61L or Ext61L proteins 
were labeled for 4 hrs with [^HJpalmitate and then incubated for the indicated 
times in non-radioactive medium containing 200 pM non-radioactive 
palmitate. Ext61L proteins were immunoprecipitated, resolved by SDS-PAGE, 
and incorporated [^HJpalmitate detected by fluorography. The Ras proteins 
on the membrane were then detected by immunoblotting to allow 
[^HJpalmitate incorporation to be normalized for protein recovery (data not 
shown). 
Figure 5. ExtRas proteins cause neurite outgrowth in PC12 cells. 
PC12 cells were transfected with the indicated amounts of various Ras DNAs: (a) parental cells; (b) 10 pg p21WT; 
(c) 1 )ig Ext61L(C181/184/186S) (Ext61U3SM. (d) 1 pg ExtWT(C181/184/186S) lExtWTOSM (e) 1 pg HRas61L; (f) 
10 ng Ext61L; (g) 200 ng ExtWT. Cells were photographed using phase-contrast optics 4 days post transfection. 
Bar, 50 pm. On day 2 when outgrowths could be clearly assigned to an individual cell body, cell images were 
captured on computer and extensions on 50 transfected cells expressing either HRas61L or Ext61L were 
measured. A successfully transfected cell was defined as a cell having a flattened and adherent cell body and at 
least 1 visible outgrowth. Co-transfections of Ext61L and b-galactosidase expression plasmids showed that over 
70% of the cells were transfected, and that greater than 95% of these transfected cells possessed neurites. Ext61L 
cells had an average of 3.4 extensions/cell and 84% of these extensions were longer than 100 pm. For cells 
expressing HRas61L, the average number of outgrowths was 2.0, but only 21% of these were longer than 
100 pm. 
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Origin 
Figure 6. Identification of the nucleotide bound to ExtRas proteins. 
Transfected PC12 cells were radiolabeled with [32p]orthophosphate for 4 h and 
HRas collected by immunoprecipitation. Protein-associated radioactive GTP 
and GDP was released, separated by thin layer chromatography and detected 
by autoradiography. The data was quantitated by densitometry and the ratio 
of GTP to the total of GTP plus GDP was determined. Lane 1, HRas61L; Lane 
2, Ext61L; Lane 3, ExtWT. 
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CHAPTER 3. H-RAS C-TERMINAL MUTATION 
CHANGES EFFECTOR UTILIZATION 
A paper to be submitted to the Journal of Biological Chemistry 
Michelle A. Booden, Donald S. Sakaguchi and Janice E. Buss 
Abstract 
In PC12 ceils, H-Ras activates multiple effector proteins, which induce cell 
cycle arrest and neuronal differentiation. In order to activate these effector 
pathways HRas must be located at the plasma membrane, a process normally 
requiring attachment of famesyl and palmitate lipids to the C-terminal region. 
Although Ext61L, a palmitoylated HRas that lacks famesyl, partitioned only 40% 
with membranes, the protein caused stronger differentiation and actin 
cytoskeletal changes in PC12 cells than were caused by famesylated HRas61L. 
These exaggerrated neurite outgrowths were sensitive to inhibitory forms of 
Rho, Cdc42, and PAK, but resistant to an inhibitory Rac protein. When 
compared to HRas61L, Ext61L caused a 2-fold greater activation of endogenous 
Rac GTP-binding and a 3-fold elevation of phosphatidylinositol 3-kinase activity 
in membranes. In constrast, Ext61L activated B-Raf kinase and ERK 
phosphorylation more poorly than HRas61L. This unbalanced effector activation 
occurred without changes in the Ras effector domain. These results indicate that 
the C-terminal alterations of Ext61L are a new way to influence HRas effector 
interactions and suggest a broader role of the lipidated C-terminus in HRas 
biological functions. 
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Introduction 
Ras proteins are monomeric GTP-binding proteins that operate as 
inducers of signal transduction cascades that regulate cell growth and 
development (1,2). They cycle between the GDP-bound inactive and the GTP-
bound active form. In their active form, Ras proteins interact with effector 
proteins, including Raf kinases, phosphoinositide 3-kinase (PI3-K), Ral-GDS, and 
AF6 (3-9). These effectors initiate a cascade of signal transduction events, the 
combination of which is needed for full biological activity of Ras (10). 
In addition to GDP/GTP cycling, another requirement for Ras activity 
involves the correct localization of Ras proteins to the inner surface of the 
plasma membrane. Plasma membrane binding of Ras is critical for its function, 
at least in part because this allows Ras to target its effector proteins to the location 
where they encounter their substrates or can be activated. Newly synthesized 
Ras proteins are partitioned to the cytoplasmic face of the plasma membrane by a 
series of post-translational lipid modifications of the C-terminus of the protein 
(11). The first lipid to be attached, a farnesyl, appears to initiate membrane 
binding. Recent studies indicate that the endoplasmic reticulum is likely to be 
the site of first contact, with further trafficking to the plasma membrane 
occurring through as yet unstudied pathways (12,13). For H-Ras, famesylation of 
Cysl86 is followed by addition of palmitates to two adjacent cysteine residues 
(CyslSl and Cysl84). H-Ras proteins with famesyl as the only lipid are >90% 
cytosolic (14-17), but the combination of famesyl and palmitates results in >95% 
membrane binding at steady state. In addition to the lipids' roles in H-Ras 
targeting and stable association with the plasma membrane, the amino acids of 
the C-terminus are also involved in trafficking of H-Ras from the endoplasmic 
reticulum to the cell surface (17). 
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An important yet unresolved issue is whether the lipids or residues of the 
C-terminal region make a further contribution to H-Ras function by directly 
supporting interactions with specific effectors. Recent studies show that famesyl 
modification of H-Ras is important for high affinity interaction and stimulation 
of full kinase activity of Raf-1 (18-23). Famesylation is also reported to increase 
in vitro binding of H- and K4B-Ras to pllOy, a PI3-kinase catalytic subunit family 
member (24). In vitro analysis also suggests that the ability of hSOSl to promote 
guanine nucleotide exchange may be dependent on H-Ras famesylation (25). 
Earlier studies employing an activated yeast Ras2 protein indicate that 
interaction between Ras2 and adenylyl cyclase is decreased in the absence of the 
famesyl lipid modification (26,27). A possible role in effector interaction for the 
lipids and C-terminal amino acids of Ras proteins is also implied by recent work 
reporting that H- and K-Ras proteins differ in their ability to activate Raf-1 and 
PI3-kinase (28,29). The major differences between the H-Ras and K-Ras proteins 
are confined to their post-translational lipid modifications and their last twenty-
five amino acids. Although both proteins are famesylated, H-Ras is modified by 
palmitates that are attached to cysteines 181 and 184 whereas K-Ras contains no 
palmitates and has instead a polybasic domain (lysine residues 175-180). Taken 
together, these data suggest that the C-terminus of Ras proteins may provide a 
mechanism (in addition to that of the intemal effector domain) for influencing 
effector interactions. 
In previous work we had characterized Ext61L, an activated H-Ras protein 
in which the C-terminal residue of the CaaX motif for famesylation was replaced 
with 6 lysines. This design prevented famesyl attachment but retained the 
natural sites for palmitoylation at the C-terminus. The novel lipidation state of 
the Ext61L presented a new way to determine if the absence of famesyl impaired 
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any signaling pathways, in a protein that was acylated and maintained an 
interaction with membranes through its C-terminus. An alteration in fimction 
had already been noted with Ext61L— expression of the protein in PC12 cells 
caused an unusual morphological differentiation distinct from that induced by 
HRas61L with the native C-terminus. Importantly, no changes had been made 
in the effector binding domain and the basic GTP binding properties of Ext61L 
were preserved, indicating that these primary requirements for effector 
interaction were unaltered. Here we describe results that suggest that the 
accentuated differentiation produced by Ext61L results from heightened 
activation of one Ras effector (PI-3 kinase) and suboptimal activation of another 
(B-Raf). These observations lend support to the idea that Ras:effector 
interactions may be influenced, in addition to the GTP-sensitive switch regions 
of the protein, by the C-terminal domain. 
Materials and methods 
Plasmids and Transfactions. Construction and expression of H-Ras61L and 
Ext61L in the pcDNA3 vector has been described previously (Booden '99). 
Plasmids driving expression of myc-tagged myc-PAKl(l-205) and Myc-PAK1(165-
205) were gifts from Gary Bokoch (La Jolla, CA) and have been described 
elsewhere (30). Myc-Rac(17N), HA-Rac(WT), and Myc-Cdc42(17N) were also gifts 
from Gary Bokoch. pllO-CAAX was a gift from Julian Downward. Ap85, Myc-
Rac(12V), Myc-RhoA(14V), and Myc-RhoA(19N) that utilized the pEXV3 vector 
were gifts from Gideon Bollag (ONYX Pharmaceuticals) and Lawrence Quilliam 
(Indianapolis, IN). Wild type B-Raf and inositol 4-phosphatase (4-PTase) in the 
pcDNA3 vector were gifts from Geoff Clark (Bethesda, MD) and F. Anderson 
Norris (Ames, lA). The Mek inhibitor PD098059 and the PI3-kinase inhibitor 
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LY294002 were purchased from Calbiochem (Lajolla, CA) and used at a 
concentration of 50 joM unless otherwise indicated. 
Twenty-four hours before transfection, PC-12 cells were plated onto 60 mm 
tissue culture dishes coated with laminin (lOpg/ml; GIBCO-BRL; Gaithersburg, 
MD) and grown overnight. Transfections were performed using the 
Lipofectamine reagent (GIBCO-BRL; Gaithersburg, MD) as described by the 
manufacturer. Quantitation of the percentage of cells bearing neurites was 
performed on day 2 and biochemical assays were performed on day 4. Co-
transfection of the above constructs with 61L or Ext61L did not affect the 
expression of 61L or Ext61L. Expression of wild type or activated forms of RhoA, 
Racl, and Cdc42 failed to promote PC12 neurite formation (data not shown). 
However, the Ap85 mutant effectively suppressed HRas61L and Ext61L-mediated 
neurite formation (data not shown) 
Immunofluoresence. PC-12 cells were plated on laminin-coated 18 mm 
coverslips in serum-containing media. 24 h after plating, the cells were 
transfected as described above and cultured for 4 days. The cells were then 
washed in PBS and fixed in fresh 4% paraformaldehyde in 0.1 M phosphate 
buffer for at least 30 min at room temperature. Cell membranes were 
permeabilized by incubation of cells in 0.2% Triton X-100, 5% goat serum, and 
0.4% BSA in PBS for 20 min at room temperature. 1 ml of 1/400-diluted 
rhodamine isothiocyanate (RITC)-phalloidin (Molecular Probes; Eugene, Oregon) 
in PBS was added to each plate. After a 20 min incubation, plates were washed 5 
times in PBS and the cover slips mounted on a glass slide with Vectashield 
(Vector Laboratories; Burlingame, CA). Fluorescence was detected with a Nikon 
microscope equipped with a 60x oil objective (1.0 numerical aperture) and 
photographs were captured using NIH Image. 
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Preparation of subcellular fractions; co-immunoprecipitation assays and 
immunoblotting. Cytosol and crude membrane fractions were separated by 
hypotonic lysis and high speed centrifugation as described (31). For detection of 
interaction between H-Ras and PI3-kinase, the PlOO membrane-contairung pellets 
were dissolved in Buffer A [20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.3 
mM DTT, 0.5mM PMSF, 1% Triton X-100, 10 jig/ml aprotinin, and 10 )Jg/ml 
leupeptin]. The SlOO cytoplasmic fractions were adjusted to the composition of 
Buffer A and HRas or PI3-kinase immunoprecipitates formed with 150 ^ig total 
protein from each fraction as described (32). Protein concentration was 
determined using the DC Protein Assay kit (Rio-Rad) and BSA standards. To 
detect interaction between Fl-Ras and B-Raf, PlOO membrane pellets were 
dissolved in Buffer B [70 mM ^-glycerophosphate (pH 7.2), 100 |iM Na3V04, 2 
mM MgCb, 1 mM EGTA, 0.5% Triton X-100, 1 mM DTT, 5 |ig/ml leupeptin, and 
20 pg/ml aprotinin]. The SlOO fractions adjusted to the composition of Buffer B 
(33), and 150 pg of total protein from each fraction used to form either H-Ras or 
B-Raf immunoprecipitates. H-Ras, B-Raf or PI3-kinase proteins were 
immunoprecipitated using anti-H-Ras rat monoclonal antibody (Y13-238; Santa 
Cruz Biotechnology), anti-p85a rabbit polyclonal serum (cat. # 06-195, UBl), or 
anti-B-Raf rabbit polyclonal serum (cat.# C19, Santa Cruz Biotechonology). 
Immunoprecipitates were captured on protein G agarose beads (GIBCO-BRL; 
Gaithersburg, MD), washed 3 times in their respective lysis buffer, and analyzed 
for co-immunoprecipitating proteins by immunoblotting with a p85a-specific 
mouse monoclonal antibody (UBI), H-Ras mouse monoclonal (3E4-146, Quality 
Biotech), or B-Raf goat polyclonal antibody (cat# SC166, Santa Cruz 
Biotechonology). Peroxidase-labeled secondary antibodies (anti-mouse or goat 
Pierce; Rockford, IL) were used with development by ECL (Pierce; Rockford, IL) 
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using the manufacturer's protocol. Reciprocal anti-H-Ras immunoprecipitates 
and anti-p85 or anti-B-Raf immunoblotting were uninformative as we were 
unable to detect the endogenous p85 or B-Raf proteins in H-Ras 
immunoprecipitates. 
In vitro lipid and protein kinase assays. PI3-kinase lipid kinase activity 
was measured using the in vitro assay described in reference (32). Anti p85 
immune complexes were collected from whole cell lysates (300 pg total protein) 
or from SlOO and PlOO fractions (150 pg total protein/fraction) (see above) and 
incubated with [y-^^P]ATP (10 |aCi per reaction, ICN; Costa Mesa, CA) and 
phosphatidylinositol (10 pg per reaction, Sigma) for 10 min. The phospholipids 
were extracted in CHClsrCHsOH (1:1), and separated by thin layer 
chromatography on potassium oxalate-coated silica plates (Analtech) developed 
in propanol:2 M acetic acid (65:35). Radioactive 32p.phosphatidylinositol-3 
phosphate was detected by autoradiography and the film images scarmed and 
quantified using the program ImageQuant (Molecular Dynamics). The 
radioactive phosphatidylinositol-3 phosphate product was identified on the basis 
of co-migration with an unlabeled PIP standard visualized by iodine staining. 
Duplicate p85 immunoprecipitates of those used in the kinase assay were 
resolved by SDS-PAGE and p85 detected by immunoblotting and quantified by 
scanning to determine the amounts of p85 captured in the immunoprecipitates 
(data not shown). 
The activity of the endogenous B-Raf kinase was measured with a coupled 
in vitro kinase assay. B-Raf immune complexes from whole cell lysates (300 
Hg), collected on protein A-conjugated agarose beads, were incubated with 
nonradioactive ATP and purified recombinant wild-type Mek protein (100 
pg/ml; provided by Dr. Lee Graves). After 10 min, recombinant ERK2 (250 
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jig/ml; provided by Dr. Lee Graves) was added and, after another 10 min, 
250]ig/ml myelin basic protein (Fisher) and [Y-32p]ATP (5 |iCi/assay) were added. 
The reactions were finally terminated 10 min later by the addition of 100 mM 
EDTA, reaction products spotted onto P-81 phosphocellulose paper (Whatman), 
washed in 10% phosphoric acid and incorporation of 32p into the precipitated 
myelin basic protein quantitated by scintillation counting (34) . 
Rac GTP/GDP binding. At 4 days post-transfection, PC-12 cells co-expressing 
HA-tagged RacWT (7 |ig) and either H-Ras61L (1 jjg) or Ext61L (50 ng) were 
incubated overnight in medium containing 1% dialyzed calf serum. Cells were 
then radiolabeled with 0.5-1 mCi/mL P inorganic phosphate (NEN-Dupont; 
Boston, MA) for 4 h in phosphate-free media containing 1% dialyzed calf serum. 
Cells were lysed and the Rac protein isolated by immunoprecipitation, as 
described above, using an anti-HA antibody (BabCo; Richmond, CA). GTP and 
GDP separated by thin layer chromatography as described (35) with the following 
important changes. Cells were lysed in a buffer containing 50 mM Tris-HCl, pH 
7.4, 250 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 20 }ig/ml aprotinin, 1 mM 
EGTA, 1 mM Na3V04. For more quantitative elution of Rac-bound nucleotides 
it was necessary to heat the samples to 70° C for 10' in 20 |il of buffer containing 
20 mM Tris-HCl (pH 7.4), 2 mM EDTA, 2% (w/v) SDS, 2 mM GDP, and 2 mM 
GTP. 
Results 
Ext61L induces exaggerated morphologic changes in PC12 cells. PC12 cells 
respond to overexpression of activated Ras proteins by the cessation of growth 
and the outgrowth of neurites (36-39). This differentiation process is 
characterized by rearrangements of the actin cytoskeleton at the plasma 
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membrane, leading to the formation of small lamellipodia, growth cones, and 
the subsequent extension of axon-like processes (40-45). Previously, the Ext61L 
protein had been shown to cause morphologic changes in PC12 cells that were 
easily distinguishable from those caused by HRas61L, including an increased 
number and accelerated rate of outgrowth of neurite-like structures and large 
lamellipodia with ruffles (35). This exaggerated response suggested that the 
Ext61L protein produced differentiation signals that were either exceptionally 
strong or that utilized different signaling pathways than H-Ras with a native C-
terminus and lipid modifications. 
To examine if these dramatic external morphological changes were 
accompanied by changes in the actin filaments that are normally rearranged 
during neurite outgrowth, the distribution of filamentous actin was examined by 
immunofluorescence of rhodamine-conjugated phalloidin. Control cells treated 
with NGF formed actin-rich neurites after 2 days, with growth cones visible at 
the end of the extending neurites (Fig. 1, NGF panel). Cell bodies displayed little 
flattening and low levels of filamentous actin. Similar changes in the actin 
cytoskeleton accompanied differentiation triggered by HRas61L (Fig. 1, 61L panel). 
Expression of Ext61L led to more extensive changes in actin structures. Neurites 
longer than 100 |im developed within 24 h of transfection and at 4 days post-
transfection cells exhibited marked somal flattening and very long, thin, actin-
rich neurites displaying extensive branching (Fig. 1 ExtBlL, 50 }im panel). At 
higher magnification, cortical actin and actin-containing microspikes could be 
seen in the large membrane ruffles, with short perpendicular filament bundles 
leading to the edge of the cells and truncated and poorly organized actin 
filaments throughout the cell interior (Fig. 1 ExtSlL, 25 panel). Thus the 
morphological changes caused by Ext61L involved actin cytoskeletal changes. 
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More importantly, the exaggerated features of the changes caused by Ext61L 
indicated that Ext61L, although identical to HRas in its Switch I (effector domain) 
and Switch n regions, affected the actin cytoskeleton in a distinct way. 
Inhibitory forms of RhoA, Cdc42, and PAK proteins decrease Ext61L-
triggered differentiation. Many aspects of actin cytoskeleton structure, in both 
fibroblasts and PC 12 cells, are controlled by the Rho family of GTPases, which 
include several Rho, Rac and Cdc42 proteins (43,46-52). NGF-mediated neurite 
formation in PC12 cells can be reduced by inhibiting the activity of Racl, Cdc42 or 
the PAK kinase or by activating RhoA proteins (37,48-50,53,54). Each of these 
proteins has also been reported to function downstream of HRas and to 
contribute to the effects H-Ras on the actin cytoskeleton (48,50,51,55-58). Thus 
more direct studies were undertaken to determine if these Rho family proteins 
were involved in the unusual changes in the actin cytoskeleton caused by Ext61L. 
PC12 cells were co-transfected with DNAs encoding either H-Ras61L or 
Ext61L and DNAs encoding inhibitory forms of RhoA, Cdc42 and PAK-1. The 
length, number and morphology of the resulting neurites were examined 4 days 
later by phase contrast microscopy. Because a substantial amount of Ext61L 
protein is cytosolic, the amounts of the Ras DNAs were carefully titrated to result 
in expression of equal amounts of each Ras protein in the membranes (PlOO 
fraction) of the PC12 cells (data not shown—see Fig. 4C for example). These 
amounts of DNA induced ~60% of the cells to extend outgrowths that at 4 days 
were at least 100 |im in length (twice the diameter of an untransfected cell). Co-
expression of RhoA(V14), Cdc42(17N) or PAK-l(165-205) reduced the number of 
cells with outgrowths of this length to -30% for H-Ras61L and -26% for Ext61L 
(Table 1). This indicated that Ext61L utilized RhoA, Cdc42, and PAK activities to 
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produce neurite outgrowths. In addition, the sensitivity of these pathways to 
inhibition was roughly similar in cells expressing H-Ras61L or Ext61L. 
Neurite outgrowth caused by Ext61L is resistant to inhibition of Rac 
activity. Surprisingly, expression of a dominant negative form of Racl 
(Rac(17N)) did not suppress the number of cells with neurite outgrowths nor 
decrease the rate of elongation that was induced by Ext61L protein (Table 1 and 
Fig. 2b). The Rac(17N) DNA was clearly functional, as the same amount (1 jig) of 
Rac(17N) DNA strongly suppressed formation of neurites by H-Ras61L (Table 1). 
Immunoblotting confirmed that the cells expressing Ext61L also expressed 
Rac(17N) protein (Fig. 2 inset). The lack of effect of Rac(17N) was particularly 
surprising given the prominent membrane ruffles on cells expressing Ext61L 
(Fig. 1 Ext61L, 25 nm panel) and the well-documented ability of Rac proteins to 
induce ruffling and lamellipodia formation. However, the neurites on cells co-
expressing Ext61L and Rac(17N) did display a subtle change in morphology-
processes were smooth, had only a single growth cone and no branching, and 
showed fewer ruffles and lamellipodia (Fig. 2b). This limited response to 
Rac(17N) suggested that Ext61L, rather than not signaling through Rac proteins at 
all, might instead be less sensitive to the effects of the inhibitory Rac protein than 
H-Ras61L. When titrations of the Ext61L and Rac(17N) DNAs were performed, a 
3-fold increase in Rac(17N) DNA was found to cause clear inhibition of 
outgrowths from cells co-expressing Ext61L (Fig. 3c and Table 1). To verify that 
this depressed outgrowth response was not caused by toxicity from the high 
amount of Rac(17N), the amount of Rac(17N) DNA was held constant and the 
amoimt of Ext61L DNA was decreased 5-fold. These results suggested that, rather 
than indicating failure to utilize the Rac pathway, the poor response of Ext61L-
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induced neurites to Rac(17N) might result from hyperactivation of Rac, making 
Rac(17N) less effective. 
Ext61L induces a sustained increase in GTP-bound Racl. The possibility of 
excessive stimulation of the Rac pathway was examined by comparing GTP-
binding of Rac in cells expressing Ext61L or HRas61L. PC12 cells were transfected 
with either H-Ras61L or Ext61L and, to obtain sufficient amounts of Rac for this 
direct analysis, an epitope-tagged, cellular form of Racl [HA-Racl]. This cellular 
form of Rac would replicate the sensitivity of the endogenous Rac proteins to 
Ras mediated effects on nucleotide exchange factors (GEFs) and GTPase activating 
proteins (GAPs). HA-Racl caused no effects on formation of outgrowths when 
expressed in concert with Ras proteins (data not shown). At 4 days post-
transfection, when neurites in both types of Ras-transfected cells were well 
established, the cells were labeled with 32pi and radioactive nucleotides bound to 
the HA-tagged Racl were analyzed. In undifferentiated cells in which only Racl 
had been introduced, the basal amount of GTP-bound HA-Rac(wt) averaged 8% ± 
2% (Fig. 3, lane 1). The co-expression of H-Ras61L caused a modest increase in 
Rac GTP binding, ~1.3-fold, to 10 ± 0.7% (Fig. 3, lane 2). This increase in Rac GTP 
binding was similar to the level attained during the transient stimulation of Rac 
GTP binding by PDGF that had been reported previously in porcine aortic cells 
(59). Increasing the amount of HRas61L DNA transfected did not further 
increase HA-Racl GTP binding (data not shown), suggesting that with HRas61L, 
cellular regulatory mechanisms were able to limit Rac activation to levels only 
slightly above those in control cells. However, Ext61L stimulated HA-Racl more 
strongly, resulting in a 2.1-fold increase in GTP-bound HA-Racl (17% ± 0.8%) 
(Fig. 3, lane 3). Thus even after 4 days, expression of the Ext61L protein 
continued to support increased GTP-binding to Racl. This sustained activation 
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of Rac quite likely contributes to the formation of the large lamellipodia and 
other dramatic changes in the PC12 cell actin cytoskeleton. 
Ext61L-mediated neurite outgrowth requires PI3-kinase activity. Two 
pathways linking Ras to Rac have been reported. Several studies have found 
evidence that production of 3'-phosphoinositols (PtdIns-3,4-P2 and PtdIns-3,4/5-
P3) by PI3-kinases can activate GEFs for the Rho family GTPases (60-64). 
Furthermore, both the pllOa and pllOP catalytic subunits of PI3-kinase have 
been identified as Ras effector proteins (3,4,64-66). In T lymphocytes and human 
neutrophils however, activation of Rac proteins by PI3-kinase-independent 
mechanisms have been reported (67,68) 
One of the phosphoinositides formed by PI3-kinase is 
phosphatidylinositol-3,4,-P2. To leam if PtdIns-3,4-P2 was needed for production 
of the unusual morphology caused by Ext61L, expression of an inositol 4-
phosphatase (4-PTase) was used to destroy this second messenger. Previous 
studies indicate that the family of inositol 4-phosphatases can hydrolyze the 4-
phosphate from three substrates, Ins(l,3,4)P3, Ins(3,4)P2, and PtdIns-3,4-P2 (69-72). 
These enzymes appear to have no specificity for any other phosphoinositides 
(69,70,72). The 4-PTase did not on its own cause any differentiation or changes in 
PC12 morphology (data not shown). However, co-expression of 4-PTase with 
Ext61L caused a moderate reduction in the number of cells that had outgrowths. 
Notably, in those cells which did have outgrowths, the cell bodies no longer 
displayed the distinctive lamellipodia, multiple neurites or branching that 
characterize Ext61L-mediated differentiation (data not shown). Thus, by limiting 
PtdIns-3,4-P2 accumulation the exaggerated morphology caused by Ext61L was 
suppressed and came to resemble more closely the response caused by HRas61L. 
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This result indicated that phosphoinositols played a major role in the abnormal 
outgrowths caused by Ext61L. 
Inhibitors of PI3-kinase were then used to explore if a PI3-kinase supplied 
the phosphatidylinositols used for Ext61L-induced process formation. The PI3-
kinase inhibitor LY294002 effectively decreased neurite formation that was 
induced by expression of Ext61L (Table 1). Similar results were obtained with 
wortmannin (data not shown). In addition, co-expression of Ap85, a putative 
dominant negative deletion mutant of the regulatory p85 subunit of PI3-kinase, 
also effectively suppressed Ext61L-mediated neurite formation (data not shown). 
These data indicated that neurite outgrowth induced by Ext61L was PI3-kinase-
dependent. From all of these results it thus appeared that Ext61L strongly 
stimulated production of 3'-phosphoinositides that bound the pleckstrin 
homology domains of Rac exchange factors (GEFs) and activated them to trigger 
Rac GTP binding. 
Ext61L activates PI3-K more strongly than H-Ras61L. A reasonable hypothesis 
for how Ext61L might enhance production of 3'-phosphoinositides was through 
increased binding to or activation of its direct partners, the pllO (a or (3) catalytic 
subunits of PI3-kinase. To test this possibility, the activation states of the 
endogenous PI3-kinase in PC12 cells expressing Ext61L or HRas61L were 
compared. Although it was attempted first, the small amount of p85 or pllO that 
could be captured in HRas immunoprecipitates proved to be insufficient to 
clearly distinguish PI3-K subunits from non-specific proteins by immunoblot 
detection. Therefore, immunoprecipitation of p85 (using antibody that allowed 
co-capture of pi 10 subunits) was used to isolate PI3-kinase and obtain a 
comprehensive picture of the activity of total pllO, whether associated with 
HRas or not. In cells expressing Ext61L, the total kinase activity of pi 10 was 
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fold (1.76 ± 0.5, n=3) higher than in cells expressing equivalent amounts of H-
Ras61L (Figure 4A). However, only membrane-bound Ras is thought to be 
competent for PI3-kinase activation and, unlike fully membrane-bound H-
Ras61L with the native lipid modifications, there is a substantial amount of 
cytosolic, GTP-bound Ext61L (35). Therefore a second set of assays was performed 
to leam if the increase in total PI3-kinase activity resulted from enhanced 
activation in primarily one location, or in both cytosolic and membrane 
fractions. In cells expressing HRas61L, the majority of the PI3-kinase activity was 
found in the cytosolic fraction (70% ± 4%; Figure 4B). In contrast, in cells 
expressing Ext61L, more than three-fourths of the active PI3-kinase was 
membrane-associated (82% ± 6%; Figure 4B). Cytosolic PI3-K activity was 
definitely not enhanced, and instead was diminished, while the activity of PI3-K 
in the membrane fraction was elevated --3-fold compared to its activity in 
membranes from HRas61L-expressing cells. Thus the increase in total PI3-kinase 
activity caused by expression of Ext61L resulted primarily from increased amount 
or activity of PI3-kinase that was associated with membranes. The increase in 
membrane-located PI3-kinase activity could therefore produce 3'-
phosphoinositides that could efficiently activate Rac GEFs and other cytoskeletal 
proteins that contribute to actin rearrangements during differentiation of PC12 
cells. 
To understand more of how Ext61L might be enhancing PI3-kinase activity, 
the interaction between the p85;pll0 complex and Ext61L was examined. A 
modest amount of HRas61L could be detected in p85 immunoprecipitates 
prepared from membrane fractions (Fig. 4C, middle panel). Because HRas61L is 
fully membrane-bound, no protein was detected in the soluble fraction. In cells 
expressing the Ext61L protein, which is -60% cytoplasmic, a small amount of 
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Ext61L interacted with the p85 in the cytosolic fraction. However, the amoimt of 
Ext61L in the p85 immunoprecipitate from the membrane fraction was 6-10-fold 
greater than the amount of HRas61L found in the HRas61L membrane sample 
(Fig. 4C middle panel). This increase in PI3-K:Ext61L interaction occurred 
despite the nearly equal amounts of Ext61L and HRas61L proteins that were 
available in the lysates (Fig. AC, bottom panel). Thus, much more Ext61L than 
HRas61L interacted with PI3-kinase, and the increase in binding was, as with the 
lipid kinase activity, predominant in the membrane fraction. The sum of all 
these results suggested that the unusual structure or lipidation of the C-terminus 
of Ext61L, in the absence of any mutation in the effector domain, caused 
hyperactivation of a PI3-kinase/Rac pathway that contributed to an exaggerated 
and abnormal program of neuronal differentiation in PC12 cells. 
Ext61L binding to B-Raf is increased but activation is decreased. However, 
the Rac pathway is not solely responsible for differentiation. Cooperation from 
other pathways is also required for Ras-mediated PC12 cell differentiation. To 
leam if the novel structure of Ext61L allowed it to activate all Ras effector 
proteins, or if it selectively stimulated PI3-kinase, the effect of Ext61L on the 
activity of the B-Raf/MEK/ERK pathway was examined. The synthetic 
compound, PD98059, was used to inhibit the activation of MEK (73,74) and the 
phosphorylation of its targets, ERKl and ERK2 monitored by immunoblotting. 
Treatment of PC12 cells with PD98059 almost completely blocked activation of 
ERKs caused by expression of either Ext61L or H-Ras61L (data not shown). In 
addition, PD98059 blocked Ext61L-induced differentiation of the PC12 cells as 
effectively as it blocked H-Ras61L-induced outgrowths (Table 1). Thus 
differentiation induced by Ext61L required the activity of MEK and appeared to be 
as sensitive to loss of its activity as H-Ras61L. 
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To more directly assess the interaction between Ext61L and an actual effector, 
endogenous B-Raf protein was isolated by immunoprecipitation and assayed for 
the co-immunoprecipitation of Ext61L by immunoblotting. B-Raf 
immunoprecipitates contained 6-10-fold more Ext61L than HRas61L, and these 
complexes were found specifically in the membrane-containing fraction (Fig. 5A, 
top panel). A similar dramatic increase in B-Raf:Ext61L complex formation was 
observed when a cDNA was used to overexpress B-Raf in PC12 cells co-
expressing Ext61L or HRas61L (data not shown). Thus B-Raf could bind much 
more Ext61L than HRas61L, although both proteins were GTP-bound to the same 
extent (35). This result was similar to what had been observed for interaction 
between PI3-K and Ext61L, and indicated that both effectors formed complexes 
with Ext61L remarkably well. 
Overexpression of B-Raf was then used to ask the reciprocal question of 
whether the non-farnesylated Ext61L could bind more B-Raf than could fully 
lipid-modified HRas61L. Immunoprecipitates of Ras proteins were prepared and 
probed with B-Raf antibodies. In HRas61L immunoprecipitates prepared from 
membrane-containing fractions detectable amounts of the co-expressed 
exogenous B-Raf protein could be observed. However, much more of the B-Raf 
protein was present in Ext61L immunoprecipitates from membrane fractions 
(data not shown), although equivalent amounts of membrane-associated 
HRas61L and Ext61L were available (data not shown). This result showed that 
Ext61L, even though it lacked the famesyl modification, could still bind B-Raf. 
However, full activation of Raf kinase activity requires much more than 
simple binding between the Ras effector domain and the Ras binding domain of 
Raf. To determine whether the increased association between B-Raf and Ext61L 
was translated into increased activation of B-Raf, endogenous B-Raf was captured 
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by immunopredpitation and its kinase activity measured using an in vitro assay. 
In cells expressing HRas61L, B-Raf activity was stimulated 4-fold over basal levels 
(Fig. 5B, 61L lane). In contrast, B-Raf activity in cells expressing Ext61L, although 
elevated (2-fold), was one-half that of the B-Raf activity in HRas61L-expressing 
cells (Fig. 5B, ExtSlL lane). Thus, despite the obvious increase in binding between 
B-Raf and Ext61L, this interaction produced little B-Raf activation. 
Since the MAP kinases ERKl and ERK2 play key roles in the Ras signaling 
pathway and are a further indication of B-Raf activity, the effects of Ext61L 
overexpression on ERK phosphorylation in the intact cell were examined. 
Although HRas61L expression caused a robust increase in phosphorylation of 
both ERKl and ERK2, Ext61L expression produced a noticeably smaller increase 
(Fig. 5C, lane 3). This impairment in B-Raf activation suggests either that Ext61L 
does not efficiently activate the B-Raf\MEK\ERK pathway within cells or that 
other effects of Ext61L cause downregulation of this pathway. Thus the poor 
stimulation of B-Raf activity by Ext61L was very different from its 
hyperactivation of PI3-K activity. These results demonstrate that the effects of 
Ext61L vary between effectors, leading to an unbalanced utilization of effector 
pathways that may further contribute to its unusual biological functioning. 
Discussion 
The results presented here identify the novel C-terminal structure of Ext61L 
as a new way to activate HRas and specific effector proteins and their signaling 
pathways. The data also provide direct support for the model in which binding 
of proteins to Ras-GTP, in addition to a required and non-discriminating 
interaction with the Ras effector domain, is selectively influenced by the 
lipidated C-terminal domain. 
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Ext61L differs from the many C-terminal mutants of HRas. Most C-terminal 
changes that have been studied previously have prevented one or both lipid 
modifications, and caused mislocalization to internal membranes, or prevented 
membrane binding entirely (14,16,17,75). Such C-terminal mutant proteins have 
displayed poor biological activity (17,26,76-79). Ext61L provides the first example 
of an alteration in the lipidation and C-terminus of H-Ras that is not detrimental 
to function. Although Ext61L is ultimately targeted to the plasma membrane 
(35), its novel C-terminal lipidation (palmitates but no famesyl) and polylysine 
structure clearly have the potential to change its pathway to the cell surface. The 
recently recognized endomembrane trafficking pathway of Ras proteins is 
postulated to begin with the processing of newly farnesylated Ras by the 
isoprenoid-dependent protease and methyl transferase found in the endoplasmic 
reticulum (12,13,80). Studies are underway to test if Ext61L engages this pathway 
despite its lack of famesyl, and will provide new information on requirements of 
the trafficking machinery and variations in C-terminal structure that it can 
accommodate. 
Once at the plasma membrane, the way Ext61L partitions into the bilayer or 
glycolipid-enriched subdomains ("rafts") may also be novel. It is likely that both 
the lipids attached to HRas proteins will play a significant role in this lipid 
bilayer distribution but their individual contributions remain unresolved. Some 
studies report that fully lipid-modified Ras proteins can be found in low-density 
cellular membranes, in company with several of their regulatory and target 
proteins (81-85), while others indicate that prenylation of HRas may actually 
prevent its localization to glycolipid-containing, detergent-resistant structures 
(86-88). It is not known if the distribution of HRas between such domains and 
the general lipid bilayer impacts what effector proteins will bind to HRas, nor 
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how such distribution may affect the activity of the bound effector. Whatever its 
pathway or interactions with the plasma membrane, it is clear that Ext61L 
ultimately reaches a functional location. Our findings that Ext61L binds both PI3-
kinase and B-Raf exceptionally well yet displays an unbalanced activation of 
these two effectors provides a foundation for novel studies using Ext61L to study 
how membrane trafficking, distribution and effector engagement are 
interrelated. 
Previous studies seeking to correlate individual Ras effector interactions with 
biological activity have exploited Ras proteins with mutations in the effector 
domain (residues 32-40). However, although effector domain mutations have 
proven remarkably able to prevent binding of the targeted effector, the activation 
of the remaining effectors is weakened, and the biological results of these 
mutations have been to impair Ras function. For example, V12G37 and V12C40 
Ras, which are unable to bind Raf-1, and V12S35 Ras, which does not bind PI3-K, 
are defective in transforming NIH3T3 cells (64,89). Ext61L now provides a new 
way to unbalance effector utilization without introducing mutations in the 
effector domain or affecting GTP binding. The retention of effector domain 
structure in Ext61L is shown clearly by the sensitivity of Ext61L function to such 
effector domain mutations— a Ext61L-Y40C mutant no longer causes neurite 
outgrowth (unpublished data). More importantly, at least 2 cellular responses 
mediated by Ext61L remain robust. The transforming activity of Ext61L in 
NIH3T3 cells is equivalent to that of HRas61L (35). In PC12 cells Ext61L is 
exceptionally potent, and even the cellular version, ExtWT, can cause outgrowth 
of neurites (35). Ext61L thus unbalances effector utilization through a different 
mechanism and with biological effects quite distinct from that of the effector 
domain mutants. 
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The two most prominent features of PC12 cells expressing Ext61L are the 
multiple and branched neurite outgrowths and the large lamellipodia. The 
hyperactivation of a PI3-kinase/Rac pathway that is documented in these studies 
is likely to play a key role in this imusual, actin-based morphology. It is also 
probable that the increased activity of the PI3-kinase has additional effects, such 
as activation of other pleckstrin-homology (PH) domain-containing proteins that 
regulate the actin cytoskeleton (57,63,90) or stimulation of members of the 
Akt/protein kinase B family (90-93). Ext61L strongly stimulates Akt 
phosphorylation (unpublished data), but comparison of this activation to that of 
HRas61L has not yet been done quantitatively. Ext61L thus appears to be a 
prototype for a new class of PI3-kinase-selective HRas protein in which activity of 
this effector is retained or even enhanced. Deciphering how the various unique 
characteristics of the Ext61L C-terminus contribute to this enhancement should 
reveal important aspects of Ras:PI3-kinase signaling. 
An unexpected feature of Ext61L was its poor activation of B-Raf. The 
MEK/ERK pathway, although not stimulated as well as by native HRas61L, was 
still functional, and its activity was still required, as shown by inhibition of 
neurite outgrowth with PD98059. In vitro assays indicated that the kinase activity 
of B-Raf was also limited. Such impairment might arise through an indirect 
mechanism similar to the recently reported ability of Akt to phosphorylate and 
inhibit Raf-1 (94). Conversely, the limited B-Raf activity may be a reflection of 
the novel ways Ext61L may interact with and juxtapose its bound effectors to the 
membrane. Co-immunoprecipitation studies suggest that the physical 
interaction between Ext61L and both B-Raf and PI3-kinase is retained and may 
even be enhanced. However, unlike PI3-kinase, this increased physical 
interaction between Ext61L and B-Raf is not translated into increased B-Raf 
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activity. Thus, two effector proteins (PI3-kinase and B-Raf kinase) whose 
activation states are sensitive to the unique C-terminus of Ext61L, have been 
identified in these studies. More detailed studies to characterize the 
mechanism(s) through which Ext61L produces its altered effector utilization will 
help decipher the contributions of C-terminal structure and membrane 
localization to biological function. 
The lack of a famesyl moiety may also be a crucial determinant for regulation 
of effector utilization by Ext61L. A growing body of evidence has accumulated 
suggesting and that the lipids at the HRas C-terminus, especially famesyl, can 
influence effector activation (24,25,95,96). Previously, membrane recuritment of 
effectors such as Raf was considered to be the only function of Ras in the 
activation of these proteins (97-99). Subsequent studies have have demonstrated 
an additional crucial role of Ras in the activation of Raf. This additional role 
appears to be mediated through interaction of the Raf cysteine rich domain 
(CRD) with Ras (18-22,95,96). This interaction is independent of the guanine 
nucleotide state of Ras yet seems to require C-terminal posttranslational 
modifications of Ras. More recent reports indicate that there is a structural 
conformation present in the prenylated form of Ras that is needed for a 
productive interaction with Raf-1, B-Raf and PllOy although it is not absolutely 
required for their binding (18,24,95,96). While the suboptimal activation of B-Raf 
by Ext61L stregthens the idea that HRas lipids, or the lack of them, contribute to 
effector activation, the molecular mechanism(s) of full Raf activation by 
association with a processed Ras protein is unclear. Therefore, the ExtRas 
proteins will be excellent tools to study the contributions of the famesyl moiety 
to Rasreffector interaction and activation as they lack the famesyl moiety but 
retain modest membrane association. 
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Two regions within the HRas protein have been identified that appear to be 
important for binding of effector proteins—the effector domain (residues 32 - 40), 
and Switch II residues (amino acids 62-78) (64,89,100). Since Ext61L and HRas61L 
proteins are completely identical in these regions it is unlikely the observed 
differences in B-Raf and PI3-K binding and activation states can be explained by 
differences in conformation of the currently known effector interaction surfaces. 
The differences between these proteins lie in their C-terminal residues and lipid 
modifications. It is presently unclear if the C-terminus induces a change in the 3 
dimensional conformation of the body of HRas or contributes to HRas effector 
interaction, either directly or indirectly. While the three-dimensional structures 
of truncated GDP and GTP-loaded versions have been solved on recombinant, 
bacterially produced HRas, these structures provide no information on the 
conformation of the the processed or unprocessed C-terminus as they are 
missing the last -20 amino acids (101,102). Our data demonstrating the increased 
association, in a membrane fraction (PlOO), of Ext61L with either B-Raf or PI3-K 
in comparison to the association of HRas61L with these respective proteins 
suggests that the C-terminus of Ext61L induces subtle changes in the RasGTP 
conformation that promote increased effector association. Significantly, these 
changes in association do not result obligatorily in concomitant increased 
activation. 
The data in this study emphasize striking differences in the ability of Ras 
proteins, that vary only at the C-terminus, to interact and activate two different 
Ras effector proteins, PI3-kinase and B-Raf. These studies further suggest that the 
HRas C-terminus and its lipid modifications do more than simply provide a 
hydrophobic region to aid in Ras-membrane interactions. Although the Ext61L 
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C-terminus is unique, it will be a valuable tool for deciphering the contributions 
of C-terminal structure and membrane localization to biological hmction. 
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Table 1. Inhibition of PC12 cell outgrowths. 
Ras protein ^Co-expressed Protein or Treatment 
expressed 
None RhoA 
(14V) 
Cdc42 Pak ''Rac ''Rac LY294002 
(17N) (165-205) (17N) (17N) 
PD098059 
'^(percentage of cells with outgrowths) 
HRas61L % 1 ± 2  25 30 35 32 ±5 ^n.d. 34 21 
Ext61L 60 ±3 26 25 27 64 ±4 35 ±8 27 16 
®PC12 cells were co-transfected with plasmids encoding either 61L or Ext61L and, as indicated, Myc-RhoA(14V) [1 ^ g], 
Myc-Cdc42(17N) [1 ng], Myc-PAKl (165-205) [3 ng], or Myc-Rac(17N) [1 or 3 ng] or 50 ^iM LY294002 or 50 ^M PD98059. 
^cells transfected with 1 ng DNA encoding Rac(17N) 
'^cells transfected with 3 ng DNA encoding Rac(17N) 
"^Two days later 200-400 cells from each treatment group were counted and cells with outgrowths longer than twice the 
diameter of an untransfected PC12 cell (-100 ^im) were scored as neurite bearing. 
^Numbers represent the average ± SEM of 7 experiments for cells expressing only Ras proteins, 3 independent experiments 
with cells co-expressing Ras and Rac(17N) proteins, and duplicate experiments for all other treatment. 
^n.d. = not determined 
Figure 1. Effect of Ext61L on the actin cytoskeleton of PC12 cells. 
Fluorescence of TRITC-phalloidin was used to visualize polymerized actin in PC12 cells expressing H-Ras61L or 
Ext61L or treated with 50 ng/ml NGF for 4 days. Panels labeled PC12, NGF, or 61L are at the same 
magnification as the Ext61L panel with the 25|jm scale bar. These fluorescent images were typical of cells 
expressing these constructs and similar results were recorded in four separate experiments. 
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Figure 2. Effects of Racl (17N) on formation of Ext61L-induced outgrowths. 
PC12 cells were co-transfected with plasmids encoding 61L or Ext61L and the indicated amounts of Myc-
RaclA(N17). After 4 days cells were imaged using phase-contrast microscopy. Numbers indicate the average, 
from three independent experiments, of the percent of cells (out of >200 that were counted) with at least 1 
outgrowth greater than 2 cell diameters in length. Dominant-negative Rac did not effect the expression of Ras. 
Ext61L 
61L 
RasOnly 
Rac(17N) 
b e 
l^g Racl(N17) 3)ig Racl(N17) 
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GTP 
Origin 
12 3 
Figure 3. Identification of nucleotide bound to HA-Rac proteins. 
PC12 cells were transfected with HA-Racl(wt) and either H-Ras61L or Ext61L and 
4 days later were labelled with 32p. for 4h. The HA-Rac protein was 
immnoprecipitated and bound nucleotides were eluted, separated by thin-
layer chromatography, and detected by autoradiography. The amounts of GTP 
were quantified by phosphoimage analysis. The averages, from four 
independent experiments, of the portion of HA-Rac that bound GTP was 
8±2% in cells without exogenous Ras (lane 1), 10±0.7% in cells co-expressing 
H-Ras61L (lane 2), and 17±0.8% in cells expressing Ext61L (lane 3). 
Figure 4. PI3-K is more active in cells expressing Ext61L. 
A. Whole cell lysates (300 jjg total protein) prepared from PC12 cells expressing 
H-Ras61L (lane 1) or Ext61L (lane 2) were immunoprecipitated using an anti-
p85 polyclonal antibody. PI3-kinase activity associated with the 
immunoprecipitates was measured in an in vitro lipid kinase assay using 
phosphatidylinositol as substrate. The phosphorylated products of the 
reactions were resolved by TLC, visualized by autoradiography, and 
quantified by Phospholmage analysis. The arrow indicates the radioactive 
PI3-P. The total activity of PI3-K in cells expressing Ext61L (lane 2), was 1.76 ± 
0.5 fold higher than in cells expressing H-Ras61L (lane 1). This average 
activity was determined from 3 independent experiments and representative 
activity of PI3-K in H-Ras61L transfected cells is 8519 cpm by scintillation 
countung. 
B. Cytosolic (S) and membrane (P) fractions (150 jig total protein) were prepared 
4 days after transfection from PC12 cells expressing H-Ras61L or Ext61L. p85-
immunoprecipitates were formed and activity of the captured PI3-kinase 
assessed with an in vitro lipid kinase assay. The phosphorylated products 
were resolved by TLC, visualized by autoradiography, and quantitated by 
phosphoimager analysis. Immunoblotting of duplicate immunoprecipitates 
confirmed equilavent amounts of Ras and p85 proteins in the P fractions of 
the precipitates. An average 30%±4 % of the total PI3-K activity in PC12 cells 
expressing H-Ras61L was membrane associated while 82%±6% of the total 
PI3-K activity in cells expressing Ext61L was membrane associated. These 
precentages are averaged from 4 independent experiments and a 
representative activity of membrane associated PI3-K in H-Ras61L transfected 
cells is 4268 cpm. 
Figure 4. Continued 
C. Cytosolic (S) and particulate (P) fractions (150 jig total protein) were 
prepared from PC12 cells expressing H-Ras61L or Ext61L. PI3-K 
immunoprecipitates were formed using an anti-p85 polyclonal antibody, 
resolved by SDS-PAGE, and immunoblotted with anti-p85 (upper panel) or 
anti-H-Ras [middle panel) monoclonal antibodies. An aliquot from each 
fraction was removed prior to immunoprecipitation, the proteins acetone 
precipitated, resolved by SDS-PAGE, and immunoblotted with an H-Ras 
monoclonal antibody {lower panel) to reveal the amounts of Ras proteins 
present in the fractions. 
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Figure 5. H-Ras61L is a more potent activator of B-Raf than Ext61L. 
A. Cytosolic (S) and particulate (P) fractions (150 jig total protein) were prepared 
from PC12 cells expressing 61L or Ext61L proteins. B-Raf was 
inununoprecipitated, resolved by SDS-PAGE, and immunoblotted with anti-
H-Ras. Separate aliquots of each fraction, taken before immunoprecipitation, 
were acetone precipitated and immunoblotted with anti-H-Ras to detect 
amounts of Ras proteins were present in the fractions. 
B. Whole cell lysates (300 ^g total protein) were prepared 4 days post-transfection 
from PC12 cells expressing H-Ras61L or Ext61L. B-Raf immunoprecipitates 
were formed and coupled immune complex kinase assays were performed 
utilizing recombinant Mekl and Erk2 proteins and [y-^^pjATP to ultimately 
label myelin basic protein as a substrate. The radioactivity incorporated into 
MBP was determined by scintillation counting. B-Raf activity in mock-
transfected cells set to 1.00. B-Raf activity in ceils expressing H-Ras61L 
averaged 3.95±1.4 and 2.28±0.58 in cells Ext61L. These percentages represent 
the average from 4 independent experiments and a representative activity of 
B-Raf in H-Ras61L transfected cells is 16014 cpm. 
C. Whole cell lysates (300 |ig total protein) were prepared from PC12 cells 
expressing 61L {lane 2) or Ext61L {lane 3) proteins 4 days after transfection and 
displayed by SDS-PAGE. Erkl and Erk2 proteins were detected by 
immunoblotting. Erk activation is indicated by the amount of 
phosphorylated Erk (P -Erk). 
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CHAPTER 4. TRANSIENT PALMITOYLATION SUPPORTS 
H-RAS MEMBRANE BINDING BUT ONLY PARTIAL 
BIOLOGICAL ACTIVITY 
A paper published in Biochemistry^ 
Sarah G. Coats, Michelle A. Booden, and Janice E. Buss 
Author contributions 
My first contribution to this paper involved determining the ability of the 
palmitates present in the chimeric proteins G43:Ras61L, G43:Ras61L(3S), and 
G43:Ras61L(C3,4S) to support membrane binding of an otherwise soluble 
HRasl86S protein. For this, I subcloned G43:Ras61L cDNA into the pcDNA3 
vector and subsequently constructed G43:Ras61L(3S) and G43:Ras61L(C3,4S) by 
PCR-directed mutagenesis. To examine membrane binding, subcellular 
membrane-containing and soluble fractions were prepared from PC12 cells 
transiently transfected with each construct. Proteins were resolved by SDS-PAGE 
and HRas proteins were detected by immunoblotting. The results from these 
experiments suggested that the C-terminal palmitates contributed significantly to 
the binding of G43:Ras61L with membranes. I further determined that in 
constrast to the poor activity of G43:Ras61L in focus formation assays, G43:Ras61L 
induced neuronal differentiation of PC12 cells. Using the biological read-out of 
PC12 cell differentiation and the G43:Ras61L(3S) and G43:Ras61L(C3,4S) chimeras, 
I determined that G43:Ras61L biological activity required palmitate modification 
of the C-terminus of Ras and that N-terminal palmitoylation contributed very 
^Reprinted with the premission of Biochemistry, 1999, 38(39), 12926-12934. 
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little to the biological activity of G43:Ras61L. The results of my contributioris are 
represented in Table 1 and Figures 1, 3A, 3B, and 5. 
Abstract 
H-Ras is >95% membrane-bound when modified by farnesyl and 
palmitate, but <10% membraiie-bound if orUy famesyl is present, implying that 
palmitate provides major support for membrane interaction. However the 
direct contribution of palmitate to H-Ras membrane interaction or the extent of 
its cooperation with farnesyl is unknown, because in the native protein the 
isoprenoid must be present before palmitate can be attached. To examine if 
palmitates can maintain H-Ras membrane association despite multiple cycles of 
turnover, a nonfarnesylated H-Ras(Cysl86Ser) was constructed, with an N-
terminal palmitoylation signal, derived from the GAP-43 protein. Although 
40% of the GAP43:Ras(61Leu,186Ser) protein (G43:Ras61L) partitioned with 
membranes, the chimera had less than 10% of the transforming activity of fully 
lipidated H-Ras(61Leu) in NIH 3T3 cells. Poor focus formation was not due to 
incorrect targeting or gross structural changes, because G43:Ras61L localized 
specifically to plasma membranes and triggered differentiation of PC12 cells as 
potently as native H-Ras61L. Proteolytic digestion indicated that in G43:Ras61L 
both the N-terminal and the two remaining C-terminal cysteines of G43:Ras61L 
were palmitoylated. A mutant lacking all three C-terminal Cys residues had 
decreased membrane binding and differentiating activity. Therefore, even with 
correct targeting and palmitates at the C-terminus, G43:Ras61L was only partially 
active. These results indicate that although farnesyl and palmitate share 
responsibility for H-Ras membrane binding, each lipid also has distinct 
functions. Famesyl may be important for signaling, especially transformation. 
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while palmitates may provide potentially dynamic regulation of membrane 
binding. 
Introduction 
Membrane binding of H-Ras is accomplished through a series of 
posttranslational modifications to its carboxy terminus: covalent attachment of 
the C15 isoprenoid, famesyl (1-4), proteolytic removal of the three C-terminal 
residues, methylation of the famesylated cysteine, and palmitoylation of two 
nearby cysteines. The two types of lipid modifications differ significantly in the 
stability of their attachment. Famesyl becomes attached permanently to H-Ras at 
Cysl86 (2). Palmitate can be added to H-Ras at two sites, CyslSl and Cysl84, (3, 5), 
but, in contrast to famesyl, is attached reversibly, undergoing cycles of removal 
and addition with a half-time of 1-2 h (6, 7). 
Membrane binding of H-Ras has received a great deal of attention because 
it is a property that is critical for its ability to function in intracellular signaling 
(8-10). However, the individual contributions of famesyl and palmitate, or the 
extent of their cooperation in membrane attachment has not been clarified. 
Famesylation occurs first, and initiates membrane localization, and thus is in 
temporal control of this event. The role of palmitate in membrane association of 
H-Ras is not well-defined because the prerequisite of famesylation has forced 
existing models to be built largely from mutants which lack this lipid. When 
modified by both famesyl and palmitate, H-Ras is >95% membrane bound and 
fully active; with famesyl as the only lipid, <10% of the H-Ras is attached to 
membranes, and biological activity is severely compromised (11-14). This shows 
that the famesyl group by itself can support only a minimal amount of H-Ras 
membrane association and implies that palmitates are needed for full plasma 
membrane interaction. However, because such mutants show decreases in both 
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membrane interaction and function, these results cannot answer whether 
palmitate or famesyl make distinct contributions or share responsibility for both 
events. 
An additional difficulty for studies of palmitoylation is the chemical 
lability of the palmitoyl-cysteine thioester linkage (5), which has prevented a 
direct assessment of the stoichiometry of H-Ras palmitoylation. Although H-Ras 
has two cysteines that can be palmitoylated, it is still not known what portion of 
these sites are occupied, or need to be, to attain the >95% membrane binding seen 
at steady state. In vitro measurements with fully di-palmitoylated peptides have 
shown that two acyl groups enable peptides to bind strongly to artificial 
membranes (15). However, in a biological setting it is unclear if the dynamic 
turnover of the palmitates might limit or set a threshold on the ability of the acyl 
groups to maintain membrane tethering of H-Ras. 
We therefore sought ways to clarify to what extent transiently attached 
palmitates can, by themselves, maintain H-Ras interactions with membranes, 
and whether H-Ras needs both palmitates and a permanently attached famesyl to 
achieve a biologically functional level of association. 
A nonfamesylated mutant of H-Ras (ExtRas) that is palmitoylated at the 
original C-terminal sites has previously been designed (16). ExtRas has six 
lysines added to its C-terminus, that are designed to initiate membrane 
interaction via ionic forces and subsequently enable the protein to be 
palmitoylated. Approximately 40% of ExtRas binds to membranes, and the 
protein has transforming activity equivalent to H-Ras61L with the native lipid 
modifications. Surprisingly, in both cellular and activated 61Leu forms, ExtRas 
causes an unusual and exaggerated differentiation of PC12 cells (16), and the 
effector protein, phosphatidylinositol 3'-kinase, binds ExtRas(61Leu) roughly 6-
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fold more effectively than H-Ras 61L with the full native lipid modifications 
(MAB and JEB, manuscript in preparation). This combination of C-terminal 
palmitates and lysines thus appears to alter signaling in addition to supporting 
membrane association. 
Therefore, a palmitoylated H-Ras protein with a C-terminus that was 
unaltered, except for the lack of a famesyl, was desired, to maintain as nearly as 
possible the conformation and interactions of this domain. For this purpose a 
chimeric Ras protein was created, by fusing a leader sequence, derived from the 
GAP-43 protein (17), to the amino terminus of H-Ras(Cysl86Ser). GAP-43, also 
known as B-50 or neuromodulin, is palmitoylated at its amino terminus, on 
Cys3 and Cys4 (18, 19). Attachment of the N-terminal 11 residues of GAP-43 has 
been shown to enable a soluble protein to become palmitoylated and membrane-
bound (17, 18, 20). Importantly, palmitoylation of GAP-43 is a dynamic 
modification, with a turn-over rate of the GAP-43 palmitates that is similar to 
those of H-Ras (18). 
In G43:Ras61L both the introduced N-terminal and the retained, native C-
terminal cysteines appeared to be palmitoylated. This provided an opportunity 
to examine membrane binding and biological activity of a G43:Ras61L protein 
with a C-terminus whose only change was a specific lack of isoprenoid. The 
results indicate that, in the setting of the intact cell, dynamic acylation of both N-
and C-terminii can support significant H-Ras membrane binding and one type of 
biological activity (differentiation). However, a second type of biological 
outcome, transformation, appeared to be particularly sensitive to the absence of 
famesyl and the palmitate-dependent balance of membrane binding. 
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Materials and Methods 
Construction of Chimeric G43:Ras61L Genes. The DNA for a protein 
termed G43ii61L was constructed first, using a small oligonucleotide designed to 
encode the first 11 amino acids of neuronal growth cone protein GAP-43, and the 
first 5 amino acids of H-Ras. The human H-Ras gene, from the HindUl site at 
codon 5 through the 3' noncoding region, containing a Cysl86Ser mutation (to 
prevent prenylation of Ras) and an activating Gln61Leu mutation (61L) was 
excised from a donor vector by simultaneous digestion with Hindlll and BamHl 
restriction endonucleases. The pcDNA3 vector (InVitrogen) was digested at the 
unique BamHl site in the Multiple Cloning Region, and the three components 
(vector, oligonucleotide, and H-Ras) were joined by ligation (22). The presence of 
the correct nucleotide sequence in the final clones selected was confirmed by 
DNA sequencing. Polymerase chain reaction (PCR) was then used to create 
G43io61L a new chimeric gene identical to the first with the exception that 
methionine 1 of H-Ras was deleted (Figurel). The original G43ii61L constructs 
were used as templates for the reaction, and primers were designed to encode the 
first 11 codons of GAP-43, and codons 2-5 of H-Ras as well as a BamHl restriction 
site at each end. The chimeric protein which lacked all three C-terminal 
cysteines, G43io61L(3Ser), was constructed by PCR using the G43io61L DNA as 
template and a mutagenic oligonucleotide for the 3' end of the DNA. The 
protein in which the N-terminal cysteines were replaced by serines, 
G43io61L(C3,4S), was constructed in a similar fashion by PCR, using G43io61L 
DNA as template and a mutagenic oligonucleotide for the 5" end of the DNA. 
Focus Formation Assay. The G43:Ras61L genes were excised by a BamHl 
digestion and cloned into the mammalian retrovirus expression vector pZIP-
neoSV(x)l for use in NIH 3T3 cell transfection assays. DNA suitable for 
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mammalian cell transfections was prepared using a Qiagen tip-100 column 
(Qiagen). NIH 3T3 mouse fibroblasts were plated at a density of 5x10^ cells per 
60 mm dish and trar^fected the following day with 0.1-10 lag of the appropriate 
plasmid DNA using calcium phosphate-mediated transfection (22). Cells were 
treated with trypsin the following day and divided equally into four dishes: 
three for focus analysis and one for G418 selection. Cells on focus plates were 
grown in DMEM + 10% calf semm; those on G418 selection plates were grown in 
DMEM + 10% calf serum + 400 yig/mL G418 (Genetecin, Gibco-BRL). Foci were 
counted at approximately 2 weeks, and the number of foci per microgram DNA 
and the number of foci per 1000 G418 colonies calculated. 
Soft Agar Assay. NIH 3T3 cells stably expressing chimeric or control 
proteins were seeded at a density of 10^ single cells per 60 mm dish in a soft agar 
overlay of 0.4% Bacto-agar (Difco) in DMEM + 10% calf serum on top of a feeder 
layer of 0.6% Bacto-agar in the same medium. Cells were photographed after 2 
weeks. The G418-selected v-H-Ras-expressing positive control NIH 3T3 cells 
were kindly provided by B. Willumsen, Copenhagen (14). 
COS-1 and PC12 Cell Transfection. Liposome-mediated transfection was 
performed using Lipofectamine (Gibco-BRL). COS-1 cells were seeded at 
approximately 50% confluence 1 day prior to transfection, and then treated with 
100 ng of the chimeric or control gene in a pcDNA3 vector. PC12 cells were 
obtained as a kind gift from Dr. J. H. P. Skene, Duke University, and were seeded 
at approximately 25% confluence 1 day prior to transfection and then treated 
with 1 -3 |ig of the chimeric or control gene in a pcDNA3 vector, using 
Lipofectamine (16). 
Immunofluorescence. COS-1 cells that expressed chimeric or control 
proteins were plated at low density on serum-coated coverslips in 6-well culture 
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dishes. Following fixation with 2% paraformaldehyde, cells were treated with 
5% nonimmune rabbit serum to block nonspecific antibody interactions and 
0.02% saponin to permeabilize the cells. Cells were then treated with a 1:20 
dilution of Y13-172 rat monoclonal antibody specific to H-Ras followed by a 1:50 
dilution of FITC-conjugated rabbit anti-rat secondary antibody (Cappel/Organon-
Teknicon), both diluted in blocking solution, mounted in DABCO-glycerol 
solution to prevent fading, and viewed by confocal immunofluorescence 
microscopy. PC12 cells expressing chimeric or control protein were treated 
similarly, except that the blocking solution used contained 0.4% bovine serum 
albumin, 3% horse serum, and contained 0.05% Triton X-100 and 0.05% Tween-
20 instead of saponin as permeabilization agents (19). 
Fractionation. Subcellular fractions were prepared by hypotonic lysis 
followed by ultracentrifugation at 100000 x g as previously described (23). 
Repeated suspension and re-sedimenting of the P-100 fractions with hypotonic 
buffer showed that G43:Ras protein remained associated with the membranes. 
For salt treatment of the membranes, the P-100 fraction was resuspended for 30 
min on ice in hypotonic lysis buffer to which NaCl was added to achieve a 
concentration of 0.5 M. Separated fractions were treated with 4 volumes of 
acetone at 0 °C and precipitated proteins collected by centrifugation for analysis of 
total proteins; otherwise fractions were reconstituted in "high-SDS RIPA buffer" 
to final concentrations of 0.5% SDS, 1% NP-40, 1% sodium deoxycholate, 150 mM 
sodium chloride, 1% (v/v) Aprotinin (Calbiochem) for immunoprecipitation. 
For testing detergent releasability of proteins from the P-100 membrane fraction, 
the supernatant (SlOO = SI) was set aside, and the pellet from the 100000 x g spin 
was resuspended in 900 viL of TESV (50 mM Iris, pH 7.5, 2 mM EDTA, 100 mM 
NaCl, 1 mM orthovanadate, 1 ^ g/mL leupeptin, 1 mM pepstatin, 1 mM Pefabloc) 
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and 100 iiL 10% NP-40 was added. The suspension was centrifuged at 16000 x g 
for 15 min and the NP-40 extract (S2) removed. The pellet (P) was resuspended 
in 100 viL of electrophoresis sample buffer. The SI and S2 supematants were 
treated with 10 mL of ice-cold acetone for 1 h and centrifuged at 3000 rpm for 30 
min, and the precipitated proteins were dissolved in 100 nL of electrophoresis 
sample buffer. 
Radiolabeiing and Immunoprecipitation. G418-selected NIH 3T3 cells or 
lipofectamine-transfected COS-1 cells expressing chimeric or control H-Ras 
proteins were labeled 4 h with [^HJpalmitic acid (Dupont-NEN) at 1 mCi/mL and 
50pg/mL cyclohexmide, or overnight with 5-[3H]mevalonolactone (American 
Radiolabeled Chemicals) at 200 )iCi/mL, in the presence of 100 jiM compactin to 
inhibit mevalonate biosynthesis (24). After the labeling period, subcellular 
fractions were prepared as described above, or cells were lysed directly in high-
SDS RIPA buffer. Immunoprecipitation was performed with 3E4-146 mouse 
anti-H-Ras monoclonal antibody (Quality Biotech). All samples were resolved by 
SDS-PAGE and transferred to a PVDF membrane and, as needed, sprayed with 
En^Hance (DuPont/NEN) for fluorography or developed with antibody for 
Western blot analysis. 
I m m u n o b l o t t i n g .  Proteins collected by centrifugation or 
immunoprecipitation were resuspended in electrophoresis sample buffer (2% 
SDS, 10 mM sodium phosphate, pH 7.0, 10% glycerol, 5% b-mercaptoethanol, 100 
mM DTT, 0.01% bromophenol blue). After separation by SDS-PAGE, proteins 
were transferred electrophoretically to a PVDF membrane, and nonspecific 
protein binding was blocked by incubating the membrane overnight in 2.5% 
nonfat dry milk in Tris-buffered saline. Membranes were probed with primary 
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antibody 3E4-146 mouse anti-H-Ras, followed by Vectastain secondary antibody, 
alkaline phosphatase-enzyme complex, and Vectastain substrate (Vector Labs). 
Proteolytic Cleavage. The protocol was modified from one published 
previously (5). COS-1 cells expressing H-Ras61L or G43io61L were labeled with 
[3 H] palmitic acid and immunoprecipitates formed as described above. The 
samples were loaded into the wells of a 24% acrylamide SDS-PAGE gel and 
overlaid with 0.1, 1.0, or lO^igof endoprotease Glu-C {Staphylococcus aureus 
strain V8; Sigma) dissolved in a nonreducing electrophoresis sample buffer 
(same as above except only 50 mM DTT and no b-mercaptoethanol). 
Electrophoresis was started and continued until the sample dye just entered the 
separating gel; then the current was stopped and proteolysis allowed to proceed 
for 30 min at ambient temperature. Electrophoresis was continued in order to 
resolve the resulting fragments on the 24% acrylamide separating gel; then 
proteins were transferred to a PVDF membrane and labeled proteins detected by 
fluorography as described above. 
Results 
Construction and Expression of G43:RAS61L chimeras. A number of non-
famesylated chimeric H-Ras proteins with an alternative lipid modification 
(myristoylation) or transmembrane domain have been studied (11, 14, 23, 25), but 
in each of these chimeric proteins the surrogate membrane targeting motif has 
been, like the famesyl group, a permanent part of the H-Ras structure. To create 
an H-Ras in which palmitates were the only lipids and means of membrane 
attachment, a chimeric G43:Ras61L gene was designed, using the amino-terminal 
sequence of GAP-43 as a palmitoylation signal. The first 11 codons of GAP-43 
were attached as a leader to codons 2 -189 of an activated H-
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Ras(61Leu/Cysl86Ser) in which the 186Ser mutation prevented attachment of 
famesyl (Figure 1). This protein in effect only lengthened the amino terminus of 
H-Ras by 10 residues, and was therefore termed G43io61L. Immunoblots of cells 
transfected with the G43io61L construct showed the 22 kDa band expected for the 
fusion protein (see Figure 3A). Another DNA containing the 11 codons of GAP-
43 attached to the full-length 189 codons of H-Ras, termed G43ii61L, was also 
constructed. However, when the G43ii61L chimera was expressed in NIH3T3 
cells, although 70% of the protein was the size expected for the chimera, -30% of 
the protein appeared to lack the GAP-43 leader sequence as a result of occasional 
initiation of translation at the retained Metl of H-Ras, producing a 21 kDa 
protein that was found only in cytosolic fractions and, as previously shown for 
H-Rasl86Ser proteins, was not palmitoylated (data not shown). This 
characteristic of H-Ras fusion proteins had been observed previously for other 
chimeric H-Ras proteins (23). The chimeric forms of these two proteins exhibited 
similar biochemical (C-terminal palmitoylation) and biological behavior (poor 
NIH 3T3 cell focus formation and good PC12 cell differentiation), and results 
given here apply to both G43io- and G43n- forms. Two additional chimeric 
DMAs were also constructed. One, G43io61L(3Ser), had codons 181,184, and 186 
for all three of the C-terminal cysteines replaced with nucleotides encoding 
serine residues, and was designed to produce a G43:Ras61L protein that had 
palmitates only at the N-terminus and lacked all C-terminal cysteines and their 
lipids (see Figure 1). The other, G43io61L(C3,4S), replaced the N-terminal 
cysteines with serines, but retained the GAP-43 leader. The C-terminus of the 
G43io61L(C3,4S) protein had the 186Ser mutation to prevent famesylation, but 
preserved the cysteines at positior« 181 and 184. 
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G43:Ras61L is palmitoylated but not prenylated. To determine directly if 
the chimeric protein possessed the desired palmitate modification, COS-1 cells 
expressing G43io61L were labeled with [^HJpalmitic acid and the chimeric Ras 
protein isolated by immunoprecipitation. Figure 2A shows that the protein did 
incorporate palmitate, and that 100% of the palmitoylated protein partitioned 
into the P-100 fraction. After fluorographic exposure the membrane was 
developed with H-Ras-specific antibody to determine the distribution of chimera 
between S-100 and P-100 fractions. The immunoblot showed that approximately 
60% of the chimeric protein was soluble and 40% was present in the PlOO 
fraction. Because no [^HJpalmitate was present in the SlOO fraction, the 60% of 
the protein that was cytosolic therefore was not palmitoylated. The palmitates 
that were present in the membrane-bound fraction of G43io61L underwent 
turnover, with a half-life similar to the palmitates present in native H-Ras (data 
not shown). 
Cells expressing G43io61L or v-H-Ras were also incubated with 
[^HJmevalonolactone, a precursor of isoprenoids, to verify that the 186Ser 
mutation of the chimera actually prevented prenylation. G43io61L did not 
incorporate label, although the v-H-Ras protein was successfully labeled under 
the same conditions (data not shown). 
G43:Ras61L is palmitoylated at both its N- and C-terminii. G43io61L 
retains the two C-terminal cysteines at positions 181 and 184 which are the 
natural sites of palmitoylation in H-Ras. Thus it was possible that 
palmitoylation of the cysteines from the GAP-43 leader and subsequent 
membrane association of the N-terminus might allow juxtaposition of the C-
terminus to the membrane and permit the native C-terminal sites to become 
acylated. To explore this possibility, N- and C-terminal, [^HJpalmitate-labeled 
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peptides derived from G43io61L and H-Ras61L proteins were compared. The 
peptides were generated by treatment of immunoprecipitated proteins with 
endoprotease GIu-C (Staphylococcus aureus V8 endoprotease), which cleaves 
exposed pol5^eptide bonds at the carboxy-terminal side of glutamic acid residues. 
As previously demonstrated for v-H-Ras (26), protease-treated H-Ras61L 
contained three peptides that were labeled by [^HJpalmitate, with apparent 
molecular masses of 21,15, and 14 kDa (Figure 2B). The 21 kDa band was the full-
length H-Ras61L, and decreased in amount in the lanes containing more 
protease. The 14 and 15 kDa bands corresponded to digestion products which 
contained the (palmitoylated) carboxy-terminus of the H-Ras61L protein, and the 
amounts of these peptides increased with increasing amounts of protease. 
Previous experiments using [35s]cysteine-labeled v-H-Ras protein (5) had shown 
that this procedure also yields a 7 kDa fragment that contains the (non-
palmitoylated) amino-terminal region of the H-Ras protein. No ^H-labeled 
7 kDa band was detected, because the amino terminus of H-Ras61L is not 
modified by palmitate. However, the absence of [^HJpalmitate-derived label in 
this fragment indicated that [^HJpalmitate had not been metabolized and re­
incorporated as amino acids. Furthermore, the labeling of the proteins had been 
done in the presence of cycloheximide, which allowed incorporation of 
radiolabel only into those proteins which had been synthesized previously. The 
protein-attached radiolabel thus remained as lipid. 
In the case of G43io61L, four distinct palmitoylated pol5(^eptides appeared, 
with apparent molecular masses of 22, 21,15, and 14 kDa (Figure 2B). The 22 kDa 
band corresponded to the full-length G43io61L protein, and was abundant in the 
lane containing the least amount of protease. In the lane containing 
intermediate amounts of protease this band was replaced by a [^HJpalmitate-
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labeled 21 kDa band, corresponding to the apparent molecular masses of a H-
Ras61L protein with an intact carboxy terminus but lacking the N-terminal GAP-
43 leader. Because there are no Glu residues in the GAP-43 leader, the leader was 
presumably removed by cleavage at one of the several Glu residues (positions 3, 
31, 37) in the H-Ras amino terminus, generating a palmitoylated, N-terminal 
fragment too small to be retained on the gel. The 14 and 15 kDa [^HJpalmitate-
labeled bands from G43io61L had precisely the same mobility as their 
counterparts in the H-Ras61L sample, and also increased in intensity with 
increasing amounts of protease, suggesting that the same C-terminal cysteines 
were modified. The same pattern of fragments was also generated from the 
G43ii61L proteins (data not shown). Although [^HJpalmitate labeling of the N-
terminal GAP-43 leader was not detectable by this technique, the presence of 
palmitate(s) at these cysteines was inferred by the retention of membrane binding 
when the C-terminal cysteines were replaced by serines (see Figure 3A). The 
presence of palmitate at the N-terminus was also implied by the loss of 
membrane binding and activity of another mutant, G43io61L(C3,4S), which 
lacked the cysteines at positions 3 and 4 (see below). These data suggested that 
the chimeric G43:Ras61L protein was palmitoylated at cysteines in both N- and C-
terminal domains. 
Association of G43:Ras61L with membranes. The ability of the (possibly 
four) palmitates present in the chimeric G43io61L protein to support membrane 
binding of the cytosolic H-Ras(186Ser) protein was examined in more detail. The 
chimeric G43io61L protein was found to be approximately 60% in the S-100 
fraction and 40% in the P-100 in COS-1 cells (data not shown);, a similar 
proportion of membrane-bound G43io61L was also observed in transfected PC12 
cells (Figure 3A). This percentage of membrane binding is similar to that seen 
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with a GAP43-P-galactosidase fusion protein (17), which was found to be -50% 
membrane bound. As expected, the native lipidated form of H-Ras61L was 
entirely particulate. The GAP-43 leader sequence has three basic residues in 
addition to the sites for palmitoylation. These residues appeared to play only a 
minor role in the maintanence of membrane binding of G43io61L, as washing 
the membranes of the PlOO fraction with 0.5 M NaCl to release protein bound 
through ionic interactions did not release any appreciable amount of the 
chimeric protein (data not shown). In addition, the G43io61 L(C3,4S) protein, 
which had these basic residues but which could not be palmitoylated at the 
amino terminus, was >90% soluble (Figure 3A). 
If the population of protein molecules observed in the P-100 fraction 
partitioned there by virtue of the lipophilic character of the chimeric protein, 
then the protein should be released into solution upon solubilization of the 
membranes by the detergent Nonidet P-40 (NP-40). Figure 3B shows the result of 
resuspending the P-100 (100000 x g pellet) fraction in 1% NP-40 and separating the 
detergent-insoluble material from the detergent-soluble portion by 
centrifugation. The precursor of endogenous H-Ras was present in the soluble 
(SI) fraction, while mature endogenous H-Ras was found entirely in the NP-40-
soluble fraction (S2) that was released from membranes. G43io61L was found in 
all three fractions, including the NP-40 insoluble fraction. As had been found in 
COS-1 and PC12 cells, in NIH 3T3 cells G43io61L was -60% soluble. 
Approximately 30% of the chimeric protein partitioned with membranes and 
could be extracted by NP-40 (S2), while the remaining 10% partitioned with 
membranes but was not released by NP-40 (P). This behavior is reminiscent of 
full-length, native GAP-43, which displays a natural cytosolic pool of protein, 
and in which -20% of the membrane-associated form is Triton-insoluble (19). 
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Further studies will be necessary to determine if the Triton-insoluble population 
of acylated G43:Ras61L is simply denatured or is associated with specific, 
submembrane domains or structures (26). 
G43:Ras61L is localized specifically at the plasma membrane. Since there is 
no isoprenoid lipid attached to G43io61L, the membrane association of the 
protein is presumably due to the presence of palmitate on the protein. However, 
the in vivo turnover and in vitro lability of the thioester bond by which the 
palmitate is attached makes results from biochemical fractionation iiiherently 
uncertain. As a second way to assess membrane attachment, 
immunofluorescence was used to visualize the subcellular location of this 
protein in an intact cell. COS-1 cells which had not taken up DNA but were 
present on the same slide as transfected cells served as negative controls; the low 
amounts of endogenous H-Ras in untransfected COS-1 cells gave no detectable 
immunofluorescence signal. A series of confocal sections of a COS-1 cell (Figure 
3C) or of PC12 cells (Figure 5) expressing G43io61L exhibited a clear, defined 
signal of H-Ras staining at the plasma membrane. No staining of internal 
membranes was observed. These data, taken with the biochemical data described 
above, strongly indicate that G43io61L is partially palmitoylated, but not 
isoprenylated, and that the portion of the chimeric protein which binds to 
membranes is located specifically at the plasma membrane. 
G43:Ras61L transforms NIH 3T3 cells poorly. The ability of the 
palmitoylated, nonisoprenylated G43:Ras61L protein to support cellular 
transformation was determined by transfection of NIH 3T3 cells and assessment 
of focus formation and growth in soft agar. Table 1 shows the relative 
transforming activities of the chimeric proteins. The ability of G43io61L to form 
foci in NIH 3T3 cells was detectable, but very low. Expression of the chimeric 
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protein in cells derived from foci or G418-resistant colonies was confirmed by 
immunoblotting (data not shown). In comparison to the highly oncogenic H-
Ras61L, the G43ioRas61L protein caused only 2% as many foci. G43io61L protein 
also showed poor focus-forming activity (<5% of H-Ras61L) in Rati cells (data 
not shown). 
NIH 3T3 cells expressing activated H-Ras proteins which contain both 
famesyl and palmitoyl lipid modifications (e.g., H-Ras61L or v-H-Ras) exhibit a 
transformed morphology, characterized by an elongated, spindle-like cell shape 
and disorderly piling of cells in the culture dish; untransfected cells are flatter 
and rounder and form an orderly monolayer. The phenotype of G418-selected 
NIH 3T3 cells expressing G43io61L was intermediate between transformed and 
normal: cells were elongated, failed to spread on the culture dish, grew 
unchecked by cell-cell contact, and formed a partially disordered monolayer 
(Figure 4, left panels). 
To resolve more rigorously if the modest morphologic changes and focus 
formation caused by G43ioRas61L were evidence of genuine transformation, 
G418-selected cells were seeded in soft agar. Cell lines derived from 
G43ioRas61L-expressing NIH3T3 cells were able to form small colonies in soft 
agar while untransfected NIH 3T3 cells were not, and v-H-Ras-transformed cells 
formed large colonies (Figure 4, right panels). Together, these assays provide 
evidence that G43ioRas61L can produce an authentic, but poorly transformed 
phenotype in NIH 3T3 mouse fibroblasts, but at a frequency much below that of 
an oncogenic H-Ras protein with both lipid modifications. 
G43:Ras61L Induces Extension of Neurite-like Processes in PC12 Cells. PC12 
cells expressing activated H-Ras proteins cease proliferation and undergo 
neuronal-like differentiation, similar to that observed when these cells are 
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exposed to nerve growth factor (27). This biological effect, although quite 
different from the growth-promoting effects of activated H-Ras in NIH 3T3 cells, 
has also been shown to be dependent on membrane association of Ras (16, 28). 
To determine how well the G43io61L protein might be able to trigger this distinct 
biological response, PC12 cells were traiisfected and the outgrowth of neurite-like 
extensions monitored. In contrast to the poor activity of G43io61L in focus 
formation, G43io61L elicited a strong morphological response in PC12 cells 
(Figure 5). G43io61L-expressing PC12 cells developed axon-like outgrowths at the 
same rate and with the same frequency as cells expressing the fully lipidated H-
Ras61L protein (Table 1). Thus, the chimera exhibited good differentiating 
activity in PC12 cells, indicating that there were no gross structural defects caused 
by the GAP43 leader that would explain its poor transformation performance. 
Biochemical fractionation of PC12 cells showed proportions of G43io61L in S-100 
and P-100 fractions similar to those seen for COS-1 cell fractionations (data not 
shown). The outgrowths produced by the G43io61L protein did, however, 
display subtle differences from H-Ras61L-triggered extensions, having a 
smoother profile, with little ruffling of the cell body or along the extended 
outgrowth. 
Using confocal immunofluorescence microscopy and an antibody to detect 
H-Ras proteins, all cells that were visibly differentiated (cells with extensions of 
>100 lim) contained chimeric protein. G43io61L chimeric protein was localized 
at the plasma membrane of the cell body as well as in the membranes of the 
axon-like outgrowths (Figure 5E). Staining was particularly prominent at the 
distal ends of outgrowths extending from the cells; veil-like sheaths of 
membrane spread around the cell body also stained very brightly. G43:Ras61L 
therefore was not trapped on internal membranes despite the absence of famesyl 
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(29), and was both targeted efficiently to the plasma membrane and highly active 
in PC12 cells. 
C-terminal palmitoylation contributes to the biological activity of G43:Ras. 
The unexpected reestablishment of palmitoylation of the C-terminal cysteines 
made it possible to examine what role lipids at the natural sites of modification 
were playing in the differentiating activity of the chimera. This was 
accomplished by constructing a new mutant G43io61L(3Ser), in which the C-
terminal cysteines, and their possibility for lipidation, were absent. When the 
G43io61L(3Ser) protein was expressed in PC12 cells, there was clear 
differentiation, but this chimera caused fewer outgrowths (Figure 5C), which 
elongated at a much slower pace than the original G43io61L or H-Ras61L 
proteins (Table 1). Beyond 4 days post-transfection, the percentage of 
G43io61L(3Ser)-transfected cells which displayed outgrowths did not increase; 
however, in cells which had outgrowths at 4 days, those extensions eventually 
did attain lengths equivalent to those caused by G43io61L, although this process 
took 7- 10 days, rather than the ~4 days required normally after transfection of 
G43io61L. Subcellular fractionation (Figure 3A) indicated that -20% of the 
G43io61L(3Ser) protein was membrane-associated. In contrast, the 
G43io61L(C3,4S) protein, in which only the two C-terminal sites were available 
for palmitoylation, showed very poor activity in the PC12 cells (Table 1) and was 
<10% membrane associated (Figure 3A). It therefore appeared that acylation of 
the C-terminal cysteines and efficient membrane binding depended on 
establishment of N-terminal palmitoylation. Thus the GAP-43 leader, if 
palmitoylated, could initiate and maintain a modest amount of membrane 
binding and allow the G43io61L(3Ser) protein to cause PC12 cell differentiation, 
but G43io61L(3S^r)-supported differentiation was less efficient than G43io61L. 
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These biological results supported the biochemical evidence of palmitates at the 
C-terminus of the original G43io61L. The C-terminal lipids were therefore 
implicated as contributing a tangible portion of the binding of G43io61L with 
membranes and its ability to produce differentiation of PC12 cells. 
Discussion 
Dynamic acylation can sustain partial h-ras membrane binding. These 
results demonstrate that, despite their biological turnover, palmitates are capable 
of sustaining H-Ras-membrane interaction without assistance from a 
permanently attached Upid or polybasic domain. Thus, the G43:Ras61L proteins 
show that dynamic acylation is competent to perform its postulated role in 
membrane binding. However, the significant limitations in membrane binding 
of the nonfamesylated G43:Ras61L proteins (none were better than 40% 
membrane-bound) also make it clear that in the native state H-Ras needs both 
farnesyl and C-terminal palmitates to achieve a high level of membrane 
association. This suggests that in native H-Ras C-terminal palmitates may not 
assume constant responsibility for membrane interaction, and that support from 
famesyl may continue to be needed. G43:Ras61L will be useful for examining if 
palmitate removal/attachment sets a threshold or limits the H-Ras 
accumulation on membranes. 
Requirements for C-terminal palmitate attachment and membrane 
targetting. It had not been expected that G43:Ras61L would be palmitoylated at 
the natural C-terminal sites. Rigorous analysis of N-myristoylated H-Ras forms 
had not detected palmitate if short labeling periods or cycloheximide was used to 
eliminate incorporation of radiolabel as m5rristate (11, 14). Authentic C-terminal 
palmitoylation had been accomplished using basic residues attached C-terminal 
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to the CaaX motif of yeast Ras2 or H-Jlas (16, 30), but G43:Ras61L is the first design 
to accomplish acylation of these sites in a C-terminus with orUy a single amino 
acid change (186Ser). However, even with four sites available for palmitate 
attachment, 60% of G43io61L remained cytosolic, indicating that steady-state 
palmitoylation of G43io61L was less complete than for H-Ras that could be 
famesylated. Famesyl thus appears to be particularly effective for positioning H-
Ras in locations or configurations to optimize palmitate attachment and 
retention. Recent studies report that famesyl may target Ras proteins to the 
cytoplasmic face of the endomembrane system, at which sites the proteins are 
further processed, perhaps palmitoylated, and then trafficked to the plasma 
membrane (29). As G43io61L appears to be efficiently localized at the plasma 
membrane, it will be useful for determining the roles of palmitate and famesyl 
in this unexplored targeting pathway. 
Palmitoylation by itself fails to support full H-Ras function. Despite the 
presence of palmitates at its C-terminus and significant amounts of protein in 
the plasma membrane the transformation efficiency of G43:Ras61L was seriously 
decreased. The potency of G43:Ras61L in PC12 cell differentiation demonstrated 
that its low transforming activity did not result from an intrinsic defect in 
G43:Ras61L structure caused by the GAP-43 sequences. This strength of 
G43:Ras61L differentiating activity also suggests that the substantial amounts of 
cytoplasmic chimera are not likely to impede signaling by potentially binding Ras 
effector proteins in the cytosol (31-33). The current results therefore provide the 
significant finding that transformation is particularly susceptible to an 
unexplored limitation that occurs during interaction of palmitoylated 
G43:Ras61L with membranes. It will be important to determine whether this 
sensitivity results from the absence of famesyl or from a new, palmitate-
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dependent balance in general membrane binding or altered membrane 
subdomain targeting of the G43:Ras61L protein. The unusual inequality in 
transforming vs differentiating activity of G43:Ras61L may also help identify a 
subset of Ras effectors responsible for this desirable transformation-specific 
defect. 
Roles of lipids in effector interactions. This report and several others have 
shown that forms of H-Ras that have no C-terminal lipids can be biologically 
active (11, 14, 34); thus, neither palmitate nor famesyl can be strictly necessary for 
the initial protein-protein interactions between H-Ras and its effectors. 
However, recent studies suggest that an interaction between the cysteine-rich 
(zinc finger) domain of Raf and the famesyl-modified form of H-Ras is necessary 
for Raf activation (35, 36). Because non-palmitoylated H-Ras with a famesyl is 
90% cytoplasmic, one function of palmitoylation appears to be to ensure 
membrane binding so that famesylated H-Ras does not accumulate in the 
cytoplasm and potentially sequester crucial partner proteins. It remains to be 
seen if famesyl, palmitate, or amino acids in the H-Ras C-terminal domain have 
any further roles in maximizing or stabilizing effector interactions at the 
membrane. Either famesyl or palmitate could also regulate interactions of H-Ras 
with subdomains of membranes that have unique lipid compositions, (e.g., 
caveolae; (26, 37-40) ). The ability to utilize intact cells to produce G43:Ras61L 
proteins, with a palmitoylated C-terminus whose stmcture and interactions are 
as close as possible to native, while specifically lacking isoprenoid, should be 
useful for testing both models. 
The unique role of palmitate. The dynamic nature of H-Ras 
palmitoylation is its clearest distinction from famesylation and likely forms a 
crucial part of palmitate's character. There is a growing appreciation that 
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reversible palmitoylation may regulate key signal transduction pathways (41, 42, 
43). The endothelial form of nitric oxide synthase responds to bradykinin with 
an increase in palmitate turnover (44, 45). P-adrenergic receptor palmitoylation 
is sensitive to isoproterenol treatment and appears to influence receptor 
phosphorylation and desensitization (46, 47). Palmitoylation of a subunits of 
several heterotrimeric G proteins is both dynamic and responsive to hormonal 
signals (48, 49, 50, 51, 52,53, 54). Palmitoylation of the a subunit of the Gz protein 
inhibits interaction with its GAP protein and may prolong or potentiate 
signaling by this protein (55). In these examples, palmitate is more than a 
passive passenger on the acyl-protein; it is potentially an active participant in the 
signaling cycle. The G43:Ras61L proteins provide an opportunity to learn if 
palmitate, in addition to its task of membrane binding, plays this role in 
signaling in H-Ras. 
Although a great deal of effort has been given to development of 
inhibitors of isoprenoid modification as a potential means to control the 
unwanted oncogenicity of Ras proteins, our findings focus attention on control 
of palmitoylation as an opportunity for significant regulation of these proteins. 
The development of G43:Ras61L proteins should now allow studies to more 
clearly define the unique roles of palmitate and isoprenoid in Ras biological 
function. 
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Table 1. G43:Ras61L proteins are weakly transforming but have strong differentiating activity. 
DNA transfected Foci'^/LOOO colonies Relative % PC12 cells^ with Relative 
transformation outgrowths differentiation 
HRas61L 1250 1.00 54 1.0 
G43J Q61L 21 0.02 57 1.0 
G43J Q61L(3 Ser) nd*" nd 36 0.6 
G43JQ61L(C3,4S) nd nd 6 0.1 
Vector 3 0 <1 0 
Replicate 60 mm dishes of NIH 3T3 cells were transfected with 250 ng of G43io61L DNA or 25 ng H-Ras61L DNA 
in the pZIP-SV(x)neo vector and were examined for either focus formation or growth of colonies in G418. Data are 
from one transfection, with n=6 dishes each for G43io61L and n=3 for pZIP vector only and H-Ras61L. Foci per dish 
were counted and divided by the number of colonies observed on a duplicate dish used for G418 selection. The H-
Ras61L DNA gave 930 foci/mg DNA. Similar results were observed in 5 independent transfections with amounts of 
G43io61L DNA ranging from 25-1000 ng. 
^ PC12 cells were grown on laminin-coated dishes and transfected with 1 mg (3 mg for G43io61L(3Ser)) of the indicated 
DNAs, all in the pcDNA3 vector. Four days later >200 cells were counted and scored as differentiated if the cell 
displayed at least 1 outgrowth longer than 2 diameters of an untransfected cell (~100 mm). The experiment was 
replicated 4 times with similar results. 
c nd = not determined 
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N-terminus of G43io constructs 
GAP-43 H-Ras 
1 11 2 
Met-Val-Cys-Cys-Met-Arg-Arg-Thr-Lys-Gln-Val-Thr-Glu-T y r.. 
GATCCA CCATG GTG TGC TGT ATG AGA AGA ACC AAA GAG GTT ACA 
GAA TAC A 
C-terminus of G43io61L(3$er) 
H-Ras 181 184 186 
-Asp-Glu-Ser-Gly-Ser-Met-Ser-Sfr-Lys-Ser-Val-Leu-Ser (stop) 
Figure 1. N- and C-terminal amino acids and oligonucleotides used to construct 
G43io61L and G43io61L(3Ser) chimeras. GAP-43 amino acids 1-11 (underlined) 
are fused to H-Ras amino acids 2 - 189. The 2 N-terminal cysteine residues 
available for palmitoylation are italicized. In the C-terminus of G43io61L(3Ser), 
the 3 serines which replace the C-terminal cysteines that are normally lipidated 
are also italicized. 
Figure 2A. G43io61L is palmitoylated. COS-1 cells were transfected with either 
an empty pcDNA3 vector or the vector encoding G43io61L, and 48 h later were 
labeled for 4 h with [^HJpalmitic acid, lysed, and soluble, S-100 (S) and 
membrane-containing P-100 (P) fractions prepared. H-Ras protein was isolated by 
immunoprecipitation and resolved by SDS-PAGE for fluorographic exposure 
(exposure time 30 days; top panel). The membrane used to expose the film was 
then developed with H-Ras-specific antibody (bottom panel). Antibody light 
chains from the immunoprecipitate are indicated as LC. No [^HJpalmitate-
labeled protein was observed in cells transfected with vector only, indicating that 
the band observed in the upper panel is a result of the introduced plasmid rather 
than endogenous H-Ras protein. 
Figure 2B. Proteolytic digestion indicates that G43io61L is palmitoylated at its 
carboxy-terminus. COS-1 cells expressing H-Ras61L or G43io61L proteins were 
labeled with [^HJpalmitate for 4 h and H-Ras proteins isolated by 
immunoprecipitation. The samples were loaded in the wells of a 24% SDS-
polyacrylamide gel and overlaid with 0.1 mg (lanes A), 1 mg (lanes B) or 10 mg 
(lanes C) of Staphylococcus aureus V8 endoprotease and processed as described in 
Methods. Protein fragments were transferred to PVDF membrane and exposed 
to film for 60 days. Molecular weights of the [^HJpalmitate-labeled peptides are 
indicated. 
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] G43:61L 
]LC 
] G43;61L 
S ^ _S P 
Mock G43:61L 
A B C  A B C  
G43:61L HRas61L 
Figure 3A. G43io61L associates with membranes. Subcellular membrane-
containing (P) and soluble (S) fractions were prepared from PC12 cells transfected 
with 1 mg of pcDNAS vectors encoding HRas61L [61L], G43io61L, G43io61L(3Ser) 
[G43:61L3S] or G43io61L(Cys3,4,Ser) [G43:C3,4S] . Proteins were resolved by SDS-
PAGE, and H-Ras proteins detected by immunoblotting. 
Figure 3B. G43io61L can be released from the P-100 membrane-containing 
fraction by NP-40. Subcellular fractions were prepared from NIH 3T3 cells that 
were untransfected or expressing G43io61L. The cytosol (SI) was removed, the 
membrane-containing fraction was treated with NP-40, and the released NP-40 
soluble proteins (S2) separated from the NP-40 insoluble proteins (P). Proteins 
were separated by SDS-PAGE and detected by immunoblotting. In Mock 
transfected cells the lip id-modified and trimmed endogenous H-Ras protein 
appears only in the detergent-solublized, S2 fraction (asterisk) while the 
unmodified precursor of the endogneous H-Ras protein appears only in the 
soluble fraction (arrowhead); G43lo61L (arrow) appears in all three fractions. 
Figure 3C. G43io61L is targeted specifically to plasma membranes. Serial sections 
of a transfected COS-1 cells expressing G43io61L protein, viewed by confocal 
immunofluorescent microscopy, show that nearly all of the fluorescence signal is 
present at the plasma membrane of the cell. Transfected COS-1 cells were plated 
on coverslips, fixed, permeablized and incubated with monoclonal H-Ras 
antibody, followed by FITC-conjugated secondary antibody. The scale bar is 25 
mm long. 
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(top) 
(bottom) 
Figure 3 (continued) 
Figure 4. G43io61L causes changes in NIH 3T3 cell morphology and can support 
growth of NIH 3T3 cells in soft agar, {left panels) G418-selected NIH 3T3 cells 
were transfected with pZip-neoSV(x)l vector DNAs encoding the indicated 
proteins. Individual colonies displaying representative cell morphologies were 
photographed. Scale bar is 100 mm. A cells transfected with empty pZIPneo 
vector, B. G43io61L, Q. H-Ras61L. (right panels) G418-selected NIH 3T3 cell lines 
expressing the indicated forms of H-Ras were seeded in 0.4% soft agar in DMEM 
and serum. At 2 weeks, colonies of average size for each cell line were 
photographed. Scale bar is 100 mm. D. NIH 3T3 cells transfected with empty 
pZIPneo vector, £. G43io61L, £. v-H Ras . 
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Figure 5. Expression of G43io61L causes differentiation of PC12 cells. PC12 cells 
were transfected with 1 mg each of pcDNA3 vectors encoding A. H-Ras61L or B. 
and E. G43io61L or 3 mg of DNA for Q. G43io61L(3Ser) and photographed 4 days 
later (5 days for panel Q) using phase contrast optics. Scale bar is 100 mm. In 
Panel D PC12 cells transfected with empty vector remain small, rounded and do 
not display membrane extensions. The immunofluorescence signal from the 
endogenous H-Ras in these cells was too weak to be reproduced 
photographically. For panel E cells were prepared for immunofluorescence 
detection of H-Ras proteins as described in Methods, then visualized by confocal 
immunofluorescence microscopy. Scale bar is 25 mm. A montage of images of a 
cell expressing G43io61L has been assembled to show the extent of cell 
elongation. The cell on the right displays bright staining of the ends of the 
numerous shorter extensions (arrow). 
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CHAPTER 5. GENERAL DISCUSSION 
Summary of our studies 
Our studies pertain to the effects on biological activity and plasma 
membrane binding of HRas due to C-terminal modifications. While it is 
apparent that lipid modifications at the C-terminus are necessary for HRas 
membrane binding and activation, the individual role(s) of these lipids are 
currently unknown. In this study, we establish a role for (1) HRas palmitoylation 
in membrane binding and (2) the C-terminus of HRas in mediating particular 
HRas biological activities. More specifically, studies with G43:Ras61L mutants 
demonstrate that palmitoylation of the N- and C-termini, in the absence of 
farnesyl, can support significant HRas membrane binding and continues to 
mediate cellular differentiation. Additionally, our studies employing the Ext61L 
construct suggest that the addition of a polylysine domain and the lack of a 
famesyl moiety in the C-terminus of Ext61L can both alter the utilization of two 
effector pathways and influence HRas signaling. 
Lipid requirements for membrane association 
A combination of signals, that include famesylation and palmitoylation, 
are required for complete HRas plasma membrane targeting and binding (8, 9, 
12). However, the contributions of each individual lipid to membrane binding 
are not fully understood. A consensus has been developed that suggests the 
famesyl modification is a prerequisite to palmitate attachment and serves to 
initiate plasma membrane contact which allows the Ras protein to access 
putative enzymes that add and remove palmitate. The data presented in this 
study indicate that HRas can be palmitoylated at the natural C-terminal sites in 
151 
the absence of famesylation. Furthermore, the successful palmitoylation of 
Ext61L or G43:HRas61L suggests that famesyl is not part of a recognition motif for 
palmitate attachment and removal. 
Each lipid modification of HRas appears to make an important 
contribution to the stability of its membrane association. Although 
palmitoylation seems to be sufficient for HRas membrane interaction, a large 
amount of Ext61L and G43:HRas61L remains in the cytosol. This indicates that 
the combination of palmitates and a polybasic domain (Ext61L) or palmitates at 
both the N- and C-termini (G43:Ras61L) in these mutants is not as efficient in 
tethering HRas to the membrane as the natural farnesyl plus palmitates. One 
explanation for the decreased membrane association of both HRas constructs is 
the absence of a permanently attached lipid to initiate membrane contact. It is 
known for HRas that a famesyl alone is a poor membrane anchor; in fact only 
10% of the protein is membrane bound when the famesyl moiety is present (9, 
14, 32). However, the combination of a famesyl and two palmitates allows HRas 
to be >95% membrane associated. The importance of palmitoylation to 
membrane binding is also apparent in each of our Ras proteins. In the absence of 
C-terminal famesylation or palmitoylation, neither the polylysine domain of 
Ext61L (2) nor transient attachment of palmitates to the amino-terminus of 
HRasl86S (6) contributes any significant membrane interactions. Thus, the 
amount of membrane-bound Ext61L or G43:HRas61L is presumably dependent 
on the rate of palmitoylation and depalmitoylation. In the absence of the 
famesyl, any changes in the rate of palmitoylation may lead to a shift in the 
equilibrium between membrane bound and cytosolic Ras, resulting in a larger 
percentage of cytosolic Ras. Thus, further analysis of these mutants will allow us 
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to study the events that may regulate HRas palmitoylation and further 
characterize the contribution of palmitates to Ras membrane binding. 
Lipid requirements for differentiation and transformation 
Our analysis demonstrates that prenylation is not required for successful 
HRas-induced differentiation or transformation as long as the protein is correctly 
targeted to the plasma membrane. However, it does appear that the palmitate 
modification is important for the biological activity of HRas. Previous studies 
with HRas61L in which the palmitoylation sites were destroyed, 
HRas61L(C181S,C184S), led to a famesylated HRas protein that was 10% plasma 
membrane bound and was >90% deficient in NIH3T3 transformation (10, 14, 32) 
and PC12 cell differentiation (1, 21, 27). Likewise, G43:HRas61L and Ext61L 
proteins that contain mutations which prevent palmitoylation are entirely 
cytosolic and severely impaired in their abilities to promote the above biological 
activities. Restoration of -40% plasma membrane association of Ext61L or 
G43:HRas61L was observed when the relevant cysteines were available for 
palmitoylation (2, 6). Interestingly, when the biological activity was examined, 
G43:HRas61L displayed two important differences from Ext61L. First, although 
G43:HRas61L could cause neurite outgrowth in PC12 cells, with a potency similar 
to that of fully lipidated HRas61L, it transfromed NIH3T3 cells very poorly(6). 
The ability of G43:HRas61L to differentiate PC12 cells showed that the presence of 
the GAP43 leader did not inactivate the protein. However, from this data it 
appears that transformation was limited by some aspect of the G43:61L protein, 
despite its apparently correct targeting and the presence of palmitates at the 
correct C-terminal sites. Second, the Ext61L protein caused rapid and potent 
differentiation of PC12 cells that produced cells with exaggerated and elongated 
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extensions, while both HRas61L and G43:HRas61L induced a less exaggerated 
phenotype (2). It is now important to determine if this difference in biological 
activity between Ext61L and G43:HRas61L results from a new palmitate-
dependent conformation, targeting to specific sub domains of the plasma 
membrane, or the lack of a hydrophobic modification at Cysl86 in G43:HRas61L. 
These questions are currently under investigation. 
Role of the C-terminus in Ras-effector interactions 
Extensive studies have demonstrated that plasma membrane localization 
of Ras is crucial for its function and have subsequently identified effectors and 
pathways utilized by Ras (19). However, the mechanism(s) for how Ras selects 
effectors and what role, if any, the C-terminus plays in this selection process has 
remained largely unaddressed. Previous attempts to understand the 
requirements for Ras-membrane association and effector interaction resulted in 
C-terminal mutants of Ras that lacked the necessary lipids modifications and 
were subsequently inactive (10, 14, 32). Our studies with novel C-terminal 
mutants of HRas indicate that changes in the C-terminus significantly alter the 
ability of HRas to interact with and activate the effector proteins B-Raf and PI3-
kinase, in vivo. In comparison to HRas61L, Ext61L associates more efficiently 
with both PI3-kinase and B-Raf. However, it differs in its abilities to activate 
these effectors. Relative to cells expressing HRas61L, Ext61L-expressing cells have 
significantly higher PI3-kinase activity but suboptimal B-Raf activity. 
Several regions within the HRas protein have been identified that appear 
to be important for binding to and/or activating regulator or effector proteins. 
These regions include amino acids 62-78 and amino acids 102-105 (30, 33). In 
addition, amino acids 32-38 of Ras have been shown to be required for all 
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functional interactions of Ras with its downstream effectors (13, 15, 24, 30, 31). 
Since Ext61L and HRas61L proteins are completely identical in all three of these 
regions, it is unlikely that these regions account for the observed differences in B-
Raf and PI3-K activation states mediated by Ext61L. Due to the lack of a famesyl 
and the addition of a poly-lysine domain in the Ext61L protein, there are two 
factors that might account for the differential activation of B-Raf. We 
determined that the exaggerated activity of Ext61L could not be ascribed to the 
polylysine motif alone, as a nonpalmitoylated mutant of Ext61L 
(Ext61L(C181S/C184S/C186S)) was unable to induce differentiation of PC12 cells 
(2). Therefore, the lack of a farnesyl may be the crucial determinant for 
regulation of B-Raf activity. 
It remains clear that famesyl is important in Ras membrane anchoring; 
however, emerging results suggest that the lipids at the HRas C-terminus, 
especially famesyl, can influence Raf activation. Previous reports indicate that 
distinct regions of Ras bind two separate N-terminal domains in Raf (3, 7, 18, 23). 
The switch I domain of Ras (residues 32-40) binds the Ras binding domain (RBD) 
of Raf (residues 55-131) while the switch II domain of Ras (residues 59-76) binds 
the cysteine rich domain (CRD) of Raf (residues 139-184) (3, 4, 7, 20). Several 
groups have presented evidence that binding of the RBD to the Ras effector 
domain does not fully activate B-Raf or Raf-1, and that a particular stmctural 
conformation in the prenylated form of Ras is needed for full activation (11, 18, 
22, 25, 28). The requirement of Raf for a prenylated form of Ras appears to be 
distinct from the need for lipidation in order to target Raf to the plasma 
membrane (17, 28). Moreover, it seems to involve a regulatory region of Raf, the 
cysteine-rich domain, that does not bind to the effector domain of Ras. Our 
studies of Ext61L indicate that the B-Raf kinase activity was ~l/2 that of cell 
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expressing HRas61L. This limited B-Raf activation was also n\irrored by weaker 
phosphorylation of the endogenous ERKl and ERK2 kinases that lie downstream 
of B-Raf. These results suggest that the farnesyl moiety may be a crucial 
determinant in the ability of HRas to mediate full Raf kinase activity. 
Furthermore, since both the Ext61L and G43:HRas61L proteins lack a famesyl but 
retain specific biological activities, studies with these proteins will be valuable for 
determining if famesyl is needed for full activation of Raf kinases. 
Our data further indicate an increase in total PI3-kinase activity associated 
with Ext61L expression and this activity is primarily in membrane fractions. In 
addition, we also find an increased association between Ext61L and PI3-kinase in 
membrane fractions. Several studies suggest that Ras binds the pi 10 catalytic 
subunit of PI3-kinase, in a GTP dependent manner, and recruits it to the plasma 
membrane where it can phosphorylate its natural substrates, PI-4P and PI-4,5P2 
(5, 16, 24, 29). However, the mechanism(s) underlying the ability of Ras proteins 
to activate PI3-kinase is not currently understood. Previous studies suggest that 
the interaction of activated Ras proteins with the pllO subunit of PI3-kinase 
results in a conformational change of the pi 10 subunit which correlates with an 
increase in kinase activity (16). A more recent report further suggests that the 
interaction of pllOy with Ras is dependent upon the correct post-translational 
processing of Ras (26). Based on these studies one might envision Ext61L 
activating PI3-K by (1) relocalizing PI3-K to a domain where it can more easily 
produce phospholipid second messengers or (2) increasing the catalytic activity of 
PI3-K associated with ExtRas. Determining the mechanism(s) underlying the 
increase in physical binding and PI3-K activation by Ext61L will be important to 
understanding how the C-terminus changes the interaction and activation of 
PI3-kinase. Furthermore, our novel C-terminal mutants of HRas can be 
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employed to leam which Ras properties: (1) lack of a famesyl, (2) presence of 
only plamitates, or (3) presence of polylysine, influence or contribute to ExtRas or 
G43;Ras mediated effector binding and activation. These studies are especially 
important as there is currently no paradigm for how Ras proteins mediate their 
interactions with effectors. 
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